var title_f17_40_18048="Moisture chambers";
var content_f17_40_18048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moisture chamber",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18048=[""].join("\n");
var outline_f17_40_18048=null;
var title_f17_40_18049="Fasciotomy and fasciectomy chronic compartment syndrome";
var content_f17_40_18049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Fasciotomy and fasciectomy for chronic compartment syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcutaneous fasciotomy of the anterior and lateral compartments (pictured on the left) is performed using two transverse skin incisions overlying the intermuscular septum between the anterior and lateral compartments. These incisions are oriented at the proximal and distal ends of the planned fasciotomies in these compartments. Using the two skin incisions, the anterior and lateral compartments are identified and blunt-tipped (Cooley or Metzenbaum) scissors are used to extend the fascial incisions between the two incisions.",
"    <br>",
"     Fasciectomy (depicted in the image on the right) is performed through a lateral longitudinal skin incision overlying the intermuscular septum between the anterior and lateral compartments. Using this incision, standard fasciotomies of the anterior and lateral compartments are performed. In addition, a 2 x 6 cm ellipse of fascia is resected (\"fasciectomy\"), preserving the fascia overlying the intermuscular septum to ensure more complete fascial release for patients with chronic exertional compartment syndrome.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18049=[""].join("\n");
var outline_f17_40_18049=null;
var title_f17_40_18050="Incorrect lifting knees straight";
var content_f17_40_18050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    INCORRECT lifting mechanics: Knees straight/bending at the waist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18050=[""].join("\n");
var outline_f17_40_18050=null;
var title_f17_40_18051="Vaginal delivery PI";
var content_f17_40_18051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal delivery (childbirth)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a vaginal delivery, a woman pushes her baby out of her vagina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: U.S. Department of Health and Human Services Office on Women's Health. Pregnancy: Labor and birth. Available at: file://www.womenshealth.gov/pregnancy/childbirth-beyond/labor-birth.cfm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18051=[""].join("\n");
var outline_f17_40_18051=null;
var title_f17_40_18052="Perflutren lipid microspheres: Drug information";
var content_f17_40_18052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Perflutren lipid microspheres: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/44/2756?source=see_link\">",
"    see \"Perflutren lipid microspheres: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Definity&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Definity&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be given following baseline noncontrast echocardiography. Imaging should begin immediately following dose and compared to noncontrast image. Mechanical index for the ultrasound device should be set at &le;0.8.",
"     <b>",
"      Note:",
"     </b>",
"     Maximum dose is either two I.V. bolus doses or one single I.V. infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. bolus: 10 microliters (&mu;L)/kg of activated product, followed by 10 mL saline flush; may repeat in 30 minutes if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion: Initial: 4 mL/minute (or 240 mL/hour) of prepared infusion; titrate to achieve optimal image; maximum rate: 10 mL/minute (or 600 mL/hour)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]: OFP 6.52 mg/mL and lipid blend 0.75 mg/mL (2 mL) [following activation, forms a suspension containing perflutren lipid microspheres 1.2 x 10",
"     <sup>",
"      10",
"     </sup>",
"     /mL and OFP 1.1 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F208486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. bolus: Administer over 30-60 seconds, follow with 10 mL saline flush",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion rate: 4 mL/minute (or 240 mL/hour) to 10 mL/minute (or 600 mL/hour)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opacification of left ventricular chamber and improvement of delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Cardiovascular: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (&gt;30 msec, 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (secondary to QT prolongation, 8%); flushing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Abdominal pain, agitation, albuminuria, anaphylactoid reactions, anaphylactic shock, angioedema, arthralgia, atrial fibrillation, bradycardia, bronchospasm, cardiac arrest, chest pain, coma, conjunctivitis, convulsions, cough, diarrhea, dizziness, diaphoresis, dyspnea, dyspepsia, ECG abnormal, edema (pharyngeal, palatal, mouth, peripheral, localized), eosinophilia, erythema, fatigue, fever, granulocytosis, hearing impairment, hematoma, hot flashes, hyper-/hypotension, hypersensitivity reaction, hypertonia, hypoxia, injection site reactions, leg cramps, leukocytosis, leukopenia, loss of consciousness, oxygenation decreased, pain, palpitation, paresthesia, pharyngitis, pruritus, rash (including erythematous rash), respiratory arrest, respiratory distress, rhinitis, rigors, shock, stridor, supraventricular tachycardia, swelling (face, eye, lip, tongue, upper airway), syncope, tachycardia, taste perversion, throat tightness, transient ischemic attack, tremor, urticaria, ventricular fibrillation, ventricular tachycardia, vertigo, visual abnormalities, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to perflutren, octafluoropropane (OFP) or any component of the formulation; right-to-left, bidirectional, or transient right-to-left cardiac shunt; administration by intra-arterial injection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Boxed warning:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious cardiopulmonary reactions: See &ldquo;Concerns related to adverse effects&rdquo; below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Immediate treatment (including epinephrine 1:1000) should be available. Postmarketing reports of anaphylactoid reactions (eg, shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema [oropharyngeal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema) have been reported in patients with no prior exposure. Monitor for signs and symptoms of anaphylactoid reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious cardiopulmonary reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious cardiopulmonary reactions (some fatal) have occurred during or within 30 minutes following administration. Ensure patient does not have any contraindications for use. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.",
"     </b>",
"     Risk may be increased in patients with unstable cardiopulmonary conditions (eg, acute MI, acute coronary syndromes, worsening or unstable HF, serious ventricular arrhythmias).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: Transient QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (&gt;30 msec) has been observed, some with associated cardiac rhythm changes; malignant symptomatology was not observed in clinical trials. The effects of concomitant drugs have not been evaluated. Monitor patients at high risk for ventricular arrhythmias due to QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ventricular arrhythmias: High ultrasound mechanical indices with or without end-systolic triggering may cause ventricular arrhythmias. Safety of activated perflutren lipid microspheres with mechanical indices &gt;0.8 or end-systolic triggering has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac shunts: Patients with right-to-left, bidirectional, or transient right-to-left cardiac shunts should not receive perflutren lipid microsphere. Use of phospholipid encapsulated microspheres will result in microvascular occlusion and ischemia since the pulmonary particle-filtering mechanism will be bypassed resulting in a direct transfer from venous to arterial circulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Product must be activated prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F208491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown adverse effects to the fetus. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Definity Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 mg/mL (2 mL): $163.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6188463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiopulmonary reactions in all patients; in high-risk patients, closely monitor blood pressure, heart rate, oxygen saturation, cardiac rhythm monitoring (during and for 30 minutes following infusion)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F208492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Definity (AU, CN, NZ);",
"     </li>",
"     <li>",
"      Luminity (CZ, SE);",
"     </li>",
"     <li>",
"      Optison (AT, DE, GR, HN, IE, IT, NL, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activated perflutren lipid microspheres provide contrast enhancement of the endocardial borders during echocardiography.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V. bolus: 3.4 minutes; I.V. infusion: 7.1 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: OFP: not metabolized; Phospholipid component: Free fatty acids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: OFP: 1.3 minutes (healthy patients); 1.9 minutes (patients with COPD)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Herzog CA, &ldquo;Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(17):2023-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/40/18052/abstract-text/18460662/pubmed\" id=\"18460662\" target=\"_blank\">",
"        18460662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kusnetzky LL, Kalid A, Khumri TM, et al, &ldquo;Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent: Results in 18,671 Consecutive Studies,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(17):1704-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/40/18052/abstract-text/18436124/pubmed\" id=\"18436124\" target=\"_blank\">",
"        18436124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10142 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D2AB0E8FD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18052=[""].join("\n");
var outline_f17_40_18052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709204\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208499\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208500\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208509\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208501\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062254\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208484\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208474\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208486\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208485\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208507\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208489\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208477\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299852\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222234\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208482\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208491\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208503\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323664\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6188463\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208492\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208476\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208488\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10142|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/44/2756?source=related_link\">",
"      Perflutren lipid microspheres: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_40_18053="Five-grass pollen sublingual tablet: Drug information";
var content_f17_40_18053=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Five-grass pollen sublingual tablet: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/13/9428?source=see_link\">",
"    see \"Five-grass pollen sublingual tablet: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16055480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oralair&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16055488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Allergen-Specific Immunotherapy",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16055508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage strength expressed in Index of Reactivity (IR).",
"     <b>",
"      Note:",
"     </b>",
"     Initiate treatment ~4 months prior to the expected onset of pollen season and continue throughout pollen season. Patients who interrupt therapy for &le;7 days may resume therapy at last previous dose; if interruption &gt;7 days may resume therapy at last previous dose, but under medical supervision. Discontinue therapy if no improvement in symptoms after 3 pollen seasons.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Symptomatic treatment of moderate-to-severe seasonal grass pollen allergic rhinitis with or without conjunctivitis:",
"     </b>",
"     Adults &le;50 years: Sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial escalation phase: Day 1: 100 IR once; Day 2: 200 IR once; Day 3: 300 IR once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 300 IR once daily until the end of pollen season",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F16055507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage strength expressed in Index of Reactivity (IR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Symptomatic treatment of moderate-to-severe seasonal grass pollen allergic rhinitis with or without conjunctivitis:",
"     </b>",
"     Children &gt;5 years and Adolescents: Sublingual: Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Clinical efficacy has been demonstrated for 1 grass pollen season in patients &le;17 years of age (Wahn, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16055509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16055510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F16055515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet, sublingual:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Oralair&trade;: 100 IR, 300 IR [source of grass pollen:  Cocksfoot (",
"     <i>",
"      Dactylis glomerata L.",
"     </i>",
"     ), sweet vernal grass (",
"     <i>",
"      Anthoxanthum odoratum L.",
"     </i>",
"     ), rye grass (",
"     <i>",
"      Lolium perenne L.",
"     </i>",
"     ), meadow grass (",
"     <i>",
"      Poa pratensis L.",
"     </i>",
"     ) , timothy (",
"     <i>",
"      Phleum pratense L.",
"     </i>",
"     )]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16055514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16055511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the morning. Place tablet(s) under tongue until completely dissolved (~1 minute) and then swallow. In the event of a missed dose, patient should be instructed to resume therapy with next scheduled dose. Dose should not be doubled to make up for missed dose. First dose in all patients should be administered under medical supervision; each subsequent dose in pediatric patients should be done under direct adult supervision. Wash hands after handling.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16055490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of allergic rhinitis with or without conjunctivitis due to moderate to severe seasonal grass pollen. For use only in patients with clinical symptoms &ge;2 pollen seasons and who are not tolerant or responsive to conventional therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Patients should have a positive skin test and a positive titer of IgE specific to",
"     <i>",
"      Poaceae",
"     </i>",
"     grass pollen.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16055479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oralair&trade; may be confused with Singulair&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;\">",
"       <b>",
"        ALERT: Canadian Boxed Warning:",
"       </b>",
"       Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16059434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (adults 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Oral pruritus (29% to 43%), throat irritation (9% to 26%), mouth edema (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Ocular pruritus (1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear pruritus (adults 3% to 12%, children 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (11% to 25%), nasopharyngitis (8% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Facial edema (adults &le;4%), chest discomfort (1% to 2%), hypertension (adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dysphonia (3%), anxiety (1%), dizziness (children 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Atopic dermatitis (children 4%), cheilitis (children 1%), excoriation (adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (adults 3% to 5%, children 1%), lip edema (3% to 5%), oral discomfort (adults 1% to 4%), tongue edema (1% to 4%), abdominal pain (1% to 3%), glossodynia (adults 1% to 3%), oral hypoesthesia (adults 1% to 3%), gastroenteritis (adults 2%), nausea (children 2%), oral mucosal blistering (children 2%), stomatitis (2%), dry throat (adults 1% to 2%), glossitis (1% to 2%), vomiting (1% to 2%), dysphagia (adults 1%), oral pain (adults 1%), stomach discomfort (adults 1%), toothache (1%), xerostomia (adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Oral paresthesia (adults 3% to 4%), neck pain (adults 1%), weakness (children 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis (adults 6%), chalazion (adults &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (children 9%), asthma (children 7%), rhinitis (7%), tonsillitis (children 7%, adults 2%), pharyngolaryngeal pain (3% to 6%), pharyngolaryngeal edema (adults 4%), upper respiratory tract infection (4%), pharyngolaryngeal discomfort (adults 3%), bronchitis (children 2%), larynx irritation (children 2%), pharyngeal hypoesthesia (adults 2%), pneumonia (children 2%), oropharyngeal edema (adults &le;2%), throat tightness (1% to 2%), upper respiratory tract congestion (1%), viral respiratory tract infection (children 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Viral infection (adults 1% to 3%), lymphadenopathy (adults &le;2%), flu-like syndrome (children 1%), infectious mononucleosis (children 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acanthoma, acne, alopecia, analgesic asthma syndrome, anaphylaxis, angioedema, anorexia, aphonia, appendicitis, aptyalism, biliary colic, breast cyst, brucellosis, Burkitt&rsquo;s lymphoma, cervical rib syndrome, cervical root pain, cervicobrachial syndrome, circulatory collapse, circumoral edema, coccydynia, colitis, conjunctival hyperemia, Crohn&rsquo;s disease, cyst, enteritis, enterocolitis, eosinophilia, esophagitis, eyelid infection, foreign body sensation in eyes, fungal infection, fungal skin infection, gallbladder pain, gastritis, gastroesophageal reflux disorder, gastrointestinal infection, genital pruritus (female), gingivitis, hemarthrosis, herpes zoster, hyperchlorhydria, hypercholesterolemia, hypersensitivity, hypotension, insomnia, intervertebral disc protrusion, lipoma, loss of taste, measles, meningococcal infection, mouth ulceration, nasal septum deviation, neurodermatitis, ocular hyperemia, otitis externa, photodermatosis, pityriasis rosea, plasmacytoma, prurigo, scarlet fever, seizure, sinusitis, skin papilloma, streptococcal infection, syncope, synovial cyst, tachycardia, tendonitis, tenotomy, tetany, tinea barbae, tinea versicolor, tongue ulceration, tooth abscess, tooth fracture, tooth infection, torticollis, tracheitis, urinary tract infection, vaginal infection, vaginitis, varicella, varicose vein, vasovagal reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16055494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any of the allergen extracts (cocksfoot, sweet vernal grass, rye grass, meadow grass, timothy) or components of the formulation; negative cutaneous test, negative IgE antibodies, and no clinical history of disease to the particular antigens; extreme sensitivity to the specific allergen determined from previous anaphylaxis following exposure; concomitant use of beta-blockers or ACE-inhibitors; severe and/or unstable asthma (FEV",
"     <sub>",
"      1",
"     </sub>",
"     &lt;70% of predicted value); severe immune deficiency or autoimmune disease; presence of malignant diseases; oral inflammation (eg, oral lichen planus, oral ulcerations or oral mycosis)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16055495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions",
"     <b>",
"      [Canadian Boxed Warning]: Hypersensitivity, diarrhea, and angioedema were observed in clinical trials within the first year of therapy. Discontinue use immediately for severe systemic reactions and administer emergency medical treatment.",
"     </b>",
"     Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during use. Mild or moderate local reactions are likely during treatment. Instruct patients to recognize adverse reactions and their possible severity. Consider use of an antihistamine for moderate local reactions. Patients receiving drugs (eg, monoamine oxidase inhibitors, tricyclic antidepressants) that can potentiate the effects of rescue medication (eg, epinephrine) may be at risk of serious adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vaccines: Effect of vaccination during therapy has not been evaluated; vaccines may be administered during therapy if deemed appropriate after clinical assessment of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use in patients &gt;50 years of age has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactose: May contain lactose; use in patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or significant lactose allergies is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [Canadian Boxed Warning]: Only physicians experienced in the treatment of adult or pediatric respiratory allergic diseases should prescribe and initiate treatment.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Monitoring:",
"     <b>",
"      [Canadian Boxed Warning]: First dose in all patients must be administered under medical supervision; monitor for at least 30 minutes after administration.",
"     </b>",
"     Each subsequent dose in pediatric patients should be done under direct adult supervision and the patient monitored at least 30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Oral surgery/procedures: Interrupt therapy in patients undergoing oral surgery including dental extraction or other interventions where integrity of the oral mucosa may be compromised. After complete healing, therapy may be resumed at dose used prior to procedure; if interruption &gt;7 days, resume therapy under medical supervision.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16055491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16055492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16055493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data regarding use in nursing women is not available. The manufacturer labeling suggests that adverse effects are not anticipated in nursing infants.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F16055503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains lactose; not recommended for use in patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or significant lactose allergies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16055513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs/symptoms of hypersensitivity; monitor adult patients for at least 30 minutes after administration of first dose and monitor pediatric patients for 30 minutes after administration of each dose.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16055501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     While the exact mechanism has not been fully elucidated, specific immunotherapy (SIT) may act by inducing a switch from T helper 2 cell response (Th2) to T helper 1 cell (Th1) response resulting in decreased interleukin-4 (IL-4) and interleukin-5 (IL-5) and increased interleukin-10 (IL-10), production of IgG-blocking antibodies that compete with IgE antibodies for allergen binding, proliferation of regulatory T lymphocytes and cytokines, and decreases in mast cells, eosinophils, and early- and late-phase allergic responses (Leith, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Didier A, Worm M, Horak F, et al, &ldquo;Sustained 3-year efficacy of pre- and Coseasonal 5-Grass-Pollen Sublingual Immunotherapy Tablets In Patients With Grass Pollen-Induced Rhinoconjunctivitis,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2011, 128(3):559-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/40/18053/abstract-text/21802126/pubmed\" id=\"21802126\" target=\"_blank\">",
"        21802126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leith E, Bowen T, Butchey J, et al, &ldquo;Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI),&rdquo;",
"      <i>",
"       Allergy Asthma Clin Immunol",
"      </i>",
"      , 2006, 2(2):47-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/40/18053/abstract-text/20525157/pubmed\" id=\"20525157\" target=\"_blank\">",
"        20525157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wahn U, Tabar A, Kuna P, et al, &ldquo;Efficacy and Safety of 5-Grass-Pollen Sublingual Immunotherapy Tablets in Pediatric Allergic Rhinoconjunctivitis,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2009, 123(1):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/40/18053/abstract-text/19046761/pubmed\" id=\"19046761\" target=\"_blank\">",
"        19046761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87801 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18053=[""].join("\n");
var outline_f17_40_18053=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055480\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055488\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055508\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055507\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055509\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055510\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055515\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055514\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055511\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055490\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055479\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16059434\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055494\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055495\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055491\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055492\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055493\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055503\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055513\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055501\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87801|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/13/9428?source=related_link\">",
"      Five-grass pollen sublingual tablet: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_40_18054="Hemodynamics derived from transesophageal echocardiography";
var content_f17_40_18054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemodynamics derived from transesophageal echocardiography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18054/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18054/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18054/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18054/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18054/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18054/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/40/18054/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 2, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transesophageal echocardiography (TEE) can rapidly provide a comprehensive array of hemodynamic information. This is of particular importance in the critical care setting, where patients are often obtunded and mechanically ventilated; TEE aids in differentiating between the causes of hypotension, dyspnea, and chest pain. To reliably and safely apply TEE to critical care, skill, experience, and multidisciplinary approach are essential. A working relationship among intensivists, anesthesiologists, and cardiologists is an integral part of every successful critical care TEE program.",
"   </p>",
"   <p>",
"    This topic will review the hemodynamic information which can be obtained during TEE. The general indications for TEE, along with its use in specific clinical situations, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=see_link\">",
"     \"Transesophageal echocardiography: Indications, complications, and normal views\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13240?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of the left ventricle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996268\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC VARIABLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic variables that are derived from TEE are comprehensive enough to provide accurate cross-sectional information; variables that can be estimated include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac output",
"     </li>",
"     <li>",
"      Left ventricular filling pressure",
"     </li>",
"     <li>",
"      Temporal distribution of left ventricular filling",
"     </li>",
"     <li>",
"      Chamber preload",
"     </li>",
"     <li>",
"      Atrial interaction",
"     </li>",
"     <li>",
"      Pulmonary pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cardiac output",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler-derived pulmonary artery, aortic, or mitral flow signals can be used to calculate stroke volume, based on the principle that the velocity time integral (VTI) of blood flow multiplied by the cross-sectional area at any of these conduits (cm2) estimates the cardiac stroke volume. The product of stroke volume and heart rate is cardiac output.",
"   </p>",
"   <p>",
"    The VTI is the actual area under the Doppler signal obtained or the velocity-time curve; because the Doppler signal is velocity",
"    <span class=\"nowrap\">",
"     (distance/time),",
"    </span>",
"    the area under the velocity-time is",
"    <span class=\"nowrap\">",
"     distance/time",
"    </span>",
"    x time or distance. Thus the velocity time integral is referred to as the stroke distance which is the distance traveled by the sampled volume within each heart beat. Stroke distance is normally 13 to 15 cm for the pulmonary artery and 18 to 20 cm for the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This method eliminates the error introduced by estimating the cross-sectional area of the vessel and holds constant over a broad range of body surface areas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/3\">",
"     3",
"    </a>",
"    ]. For measurements of stroke distance as well as cardiac output, it is important that the Doppler beam interrogation angle is within 20&ordm; of the direction of flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link&amp;anchor=H2#H2\">",
"     \"Principles of Doppler echocardiography\", section on 'Basic principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of transesophageal echocardiography to determine cardiac output by each of these methods has been investigated. The main pulmonary artery is the most convenient site from which to measure the VTI. In the basal short axis view, pulmonary artery diameter can be measured in most patients and flow signals can be obtained using either pulsed or continuous wave Doppler. Several intraoperative studies suggest that the continuous wave Doppler is more accurate than pulsed wave when compared with thermodilution cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This method was established in the operating room by comparing it with thermodilution cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/5\">",
"     5",
"    </a>",
"    ]. Although cardiac output by thermodilution is not an ideal reference standard, the pulsed-wave Doppler method was able to follow directional changes in that parameter. In our clinical experience with this method we have been encouraged by how consistently the pulsed-wave Doppler results match standard measurements and reflect the clinical situation.",
"   </p>",
"   <p>",
"    Aortic blood flow cannot usually be accurately measured from the esophageal views because of poor ultrasound beam alignment for Doppler signals. However, using the \"deep transgastric view\" aligns the left ventricular outflow tract with the transducer to obtain accurate flow signals and permits accurate determination of the cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurements of cardiac output based on mitral flow correlate well with thermodilution cardiac output when biplane transesophageal echocardiographic measurements of the mitral annulus in the two- and four-chamber views are used to calculate the cross-sectional area as an ellipse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Left ventricular and atrial filling pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary venous flow patterns, mitral inflow signal configuration, and continuous-wave Doppler of mitral regurgitation contain information from which filling pressures can be estimated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Doppler mitral inflow velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler demonstration of the velocity profile of left ventricular transmitral inflow is the most informative TEE-based method of assessing left ventricular filling pressures (",
"    <a class=\"graphic graphic_waveform graphicRef65233 graphicRef59321 \" href=\"UTD.htm?8/58/9127\">",
"     waveform 1A-B",
"    </a>",
"    ). Important diagnostic parameters derived from the mitral inflow signals include the ratio of peak early filling velocity to late diastolic atrial filling velocity",
"    <span class=\"nowrap\">",
"     (E/A",
"    </span>",
"    ratio), the deceleration time of early filling curve (DT), and the isovolumic relaxation time (IVRT). Studies have demonstrated that the relationship between peak velocity and deceleration in early diastole with late diastolic velocities during atrial contraction is altered in diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is considerable variability, two predominant patterns of flow have been recognized that reflect the two major categories of diastolic dysfunction, ie, impaired left ventricular relaxation and decreased left ventricular compliance (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H3#H3\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Doppler mitral inflow velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impairment of left ventricular relaxation is characterized by a reduction in mitral flow velocity in early diastole, manifested by an abnormally low E wave, and increased late diastolic filling, manifested by an increased A wave; the",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio is decreased and is &lt;1 compared to normal where the",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio is &ge;1. These alterations appear to be more sensitive than the M-mode mitral filling slope [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/13\">",
"       13",
"      </a>",
"      ]. Additionally, there is prolongation of the deceleration time and the isovolumic relaxation times. This form of diastolic dysfunction occurs in ischemic heart disease, hypertension, and as a result of normal aging.",
"     </li>",
"     <li>",
"      Diminished left ventricular compliance is characterized by a \"restrictive flow\" pattern with an increased",
"      <span class=\"nowrap\">",
"       E/A",
"      </span>",
"      ratio and a shortened isovolumic relaxation time and deceleration time. This pattern occurs in patients with restrictive cardiomyopathies, such as amyloid heart disease, and in those with elevated filling pressures associated with a variety of myopathic conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the diastolic filling pattern does not always reflect these two circumscribed categories because it is influenced by a variety of other factors, including loading conditions, heart rate, pericardial restraint, left atrial pressure and compliance, right and left ventricular interaction, coronary turgor, the intrinsic properties of left atrial and left ventricular muscle, the presence or absence of mitral regurgitation, and patient age. For example, changes in loading conditions during cardiac surgery have been shown to influence filling patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/14\">",
"     14",
"    </a>",
"    ]. With an increase in intravascular volume, a rise in early diastolic filling velocity is seen, most likely due to an increased left atrial to left ventricular pressure gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/15\">",
"     15",
"    </a>",
"    ]. Similarly, an increase in left atrial pressure due to ischemia may be associated with an increase in early diastolic filling velocities, ie, pseudonormalization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, hypovolemia or preload reduction (eg, nitrates) may cause a decrease in early filling velocity mimicking impaired relaxation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pulmonary venous flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of the mitral inflow pattern is greatly enhanced when the pattern of pulmonary venous Doppler signal is examined; transesophageal echocardiography has contributed substantially to our understanding of this hemodynamic parameter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H4#H4\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Pulmonary venous flow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transesophageal echocardiography from the base of the heart demonstrates the entrance of the four pulmonary veins into the left atrium. The left upper pulmonary vein flow is close to and parallel to the direction of the interrogating beam and highly resolved color flow pulsed-wave Doppler images are readily obtained, helping to guide positioning of the sample volume into the proximal 1 cm of the vein.",
"   </p>",
"   <p>",
"    Flow in the pulmonary veins is triphasic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The systolic phase is predominant, accounting for more than 55 percent of total flow integral. The second phase occurs in early diastole and is approximately 40 percent of the total. Both of these phases move in an antegrade, central direction and occur as the result of atrial systolic filling and atrial diastolic emptying. The third phase is in late diastole and results from atrial contraction. In contrast to the first two phases, the atrial phase is retrograde and usually small (",
"    <a class=\"graphic graphic_figure graphicRef68801 \" href=\"UTD.htm?37/8/38029\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62749 \" href=\"UTD.htm?17/35/17970\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77774 \" href=\"UTD.htm?33/57/34704\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef87117 \" href=\"UTD.htm?27/1/27671\">",
"     figure 2",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Variables frequently measured from pulmonary venous flow velocity tracings with demonstrated utility include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peak systolic and peak early diastolic flow velocities",
"     </li>",
"     <li>",
"      Peak velocities of flow reversal at atrial contraction",
"     </li>",
"     <li>",
"      Velocity-time integrals of the systolic, early diastolic, and atrial contraction phases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The systolic velocity-time integral (S) is measured from the onset of forward flow following the peak R wave on the electrocardiogram to the point at which it reaches zero flow velocity. The early diastolic velocity-time integral (D) is measured from the onset of the second wave to its crossover with the zero-line. The systolic fraction is equal to",
"    <span class=\"nowrap\">",
"     S/(S",
"    </span>",
"    + D). The velocity-time integral of the late diastolic A wave (retrograde flow during atrial contraction) is measured from its onset to the end of negative flow.",
"   </p>",
"   <p>",
"    In conditions that alter left ventricular filling patterns, especially when filling pressures are elevated, systole becomes subordinate to diastole. Concurrently, retrograde atrial flow may increase and it exceeds forward atrial flow across the mitral valve in duration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/18\">",
"     18",
"    </a>",
"    ]. In severe mitral regurgitation, systolic flow reversal has been described as one of the signs of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitral inflow and pulmonary venous flow patterns are complementary [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/14\">",
"     14",
"    </a>",
"    ]. For example, restrictive mitral inflow is characterized by a short isovolumic relaxation time, a normal or slightly elevated peak velocity, a short deceleration time, and a low A wave velocity. These features result in an increased E to A ratio and a pattern known as \"pseudonormalization.\" A restrictive pattern on mitral inflow and decreased systolic fraction on pulmonary venous inflow are complementary, permitting confident recognition of elevated filling pressure. A prolonged retrograde pulmonary venous A wave and a shortened A wave on mitral inflow also connote elevated pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mitral regurgitation continuous-wave Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features of the mitral regurgitant continuous-wave Doppler flow signal are the density of the signal, which is roughly proportional to severity of regurgitation; the v-wave cutoff sign, which results from a rapid decrease in ventriculoatrial gradient as the regurgitant blood abruptly raises pressure in the left atrium; and the early systolic acceleration of the jet flow envelope, which is an expression of",
"    <span class=\"nowrap\">",
"     dP/dt",
"    </span>",
"    (the change in pressure over time). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Left ventricular and atrial chamber sizes (preload)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume changes (ie, preload) affect the size and shape of the left heart chambers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute hypovolemia, most normal hearts become hyperdynamic and develop very small end-systolic volumes. In preload sensitive hearts, contractility may decrease, but this situation is harder to recognize. The left atrium in hypovolemia may decrease in size. Similarly, the right atrium, venae cavae, and hepatic veins become small, and respiratory collapse might be appreciated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypervolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hypervolemia, as seen in congestive heart failure, especially if chronic, the left ventricle assumes a spherical state as it dilates. This appearance is strikingly different from the ellipsoid shape of the healthy heart. While one cannot determine the filling pressure from inspecting the ventricles and atria, observations of these features can reinforce the inferences drawn from Doppler data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intra-atrial septal motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The behavior of the interatrial septum is a particularly important clue as to the left ventricular filling pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18054/abstract/20\">",
"     20",
"    </a>",
"    ]. Observations made on ventilated patients showed that in the euvolemic or hypovolemic state, the interatrial septum, normally curved to the right, will reverse curvature at end expiration at both end-systole and end-diastole. The cause of the rapid reversal in curvature has been documented with flow-directed catheters; it arises from a transient reversal in the pressure differential in such a way that right atrial pressure transiently exceeds left atrial pressure during the expiratory phase of the ventilator cycle. This occurs only when pressures (pulmonary capillary wedge and central venous pressure) are low and nearly equal.",
"   </p>",
"   <p>",
"    If either atrium carries higher pressure, the atrial septum will remain bowed toward the lower pressure chamber. In mitral regurgitation, for example, the atrial septum bows from left to right, and this curvature is little affected by the respiratory cycle. In tricuspid regurgitation or pulmonary hypertension the curvature goes from right to left. It is worth emphasizing how useful this simple observation can be in \"tying together\" multiple variables and emerging with a clear picture of a patient's hemodynamics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996275\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic variables that can be estimated during transesophageal echocardiography (TEE) include cardiac output, left ventricular (LV) filling pressure, temporal distribution of LV filling, chamber preload, atrial interaction, and pulmonary arterial pressures. (See",
"      <a class=\"local\" href=\"#H15996268\">",
"       'Hemodynamic variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler-derived pulmonary artery, aortic, or mitral flow signals can be used to calculate stroke volume, based on the principle that the velocity time integral (VTI) of blood flow multiplied by the cross-sectional area at any of these conduits (cm2) estimates the cardiac stroke volume. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cardiac output'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler demonstration of the velocity profile of left ventricular transmitral inflow is the most informative TEE-based method of assessing left ventricular filling pressures. However, the transmitral diastolic filling pattern does not always reflect underlying pathology because it is influenced by a variety of other factors (eg, loading conditions, heart rate, pericardial restraint, left atrial pressure and compliance, patient age). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Doppler mitral inflow velocity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler investigation of the pulmonary venous flow patterns is another method of evaluating left-sided filling pressures and loading conditions, providing complementary information to the transmitral inflow profile. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulmonary venous flow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chamber sizes, particularly if abnormal, provide information about the preload conditions in the heart as well as potentially providing information on any underlying pathology. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Left ventricular and atrial chamber sizes (preload)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The behavior of the interatrial septum is a particularly important clue as to the intracardiac filling pressures. If either atrium carries higher pressure, the atrial septum will remain bowed toward the lower pressure chamber. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Intra-atrial septal motion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/1\">",
"      Bouchard A, Blumlein S, Schiller NB, et al. Measurement of left ventricular stroke volume using continuous wave Doppler echocardiography of the ascending aorta and M-mode echocardiography of the aortic valve. J Am Coll Cardiol 1987; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/2\">",
"      Haites NE, McLennan FM, Mowat DH, Rawles JM. How far is the cardiac output? Lancet 1984; 2:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/3\">",
"      Lim DC, Redberg RF, Foster E, et al. Stroke distance is independent of body surface area. J Am Soc Echo 1993; 6:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/4\">",
"      Urbanowicz JH, Shaaban MJ, Cohen NH, et al. Comparison of transesophageal echocardiographic and scintigraphic estimates of left ventricular end-diastolic volume index and ejection fraction in patients following coronary artery bypass grafting. Anesthesiology 1990; 72:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/5\">",
"      Muhiudeen IA, Kuecherer HF, Lee E, et al. Intraoperative estimation of cardiac output by transesophageal pulsed Doppler echocardiography. Anesthesiology 1991; 74:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/6\">",
"      Darmon PL, Hillel Z, Mogtader A, et al. Cardiac output by transesophageal echocardiography using continuous-wave Doppler across the aortic valve. Anesthesiology 1994; 80:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/7\">",
"      Katz WE, Gasior TA, Quinlan JJ, Gorcsan J 3rd. Transgastric continuous-wave Doppler to determine cardiac output. Am J Cardiol 1993; 71:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/8\">",
"      Griffin BP, Hore P, Davison K, et al. Determination of cardiac output with single and biplane transesophageal echocardiography. J Am Coll Cardiol 1991; 17:35A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/9\">",
"      Hozumi T, Shakudo M, Applegate R, Shah PM. Accuracy of cardiac output estimation with biplane transesophageal echocardiography. J Am Soc Echocardiogr 1993; 6:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/10\">",
"      Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996; 27:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/11\">",
"      Hatle L. Doppler echocardiographic evaluation of diastolic function in hypertensive cardiomyopathies. Eur Heart J 1993; 14 Suppl J:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/12\">",
"      Labovitz AJ, Pearson AC. Evaluation of left ventricular diastolic function: clinical relevance and recent Doppler echocardiographic insights. Am Heart J 1987; 114:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/13\">",
"      Bryhn M. Abnormal left ventricular filling in patients with sustained myocardial relaxation: assessment of diastolic parameters using radionuclide angiography and echocardiography. Clin Cardiol 1984; 7:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/14\">",
"      Kuecherer HF, Foster E. Hemodynamics by transesophageal echocardiography. Cardiol Clin 1993; 11:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/15\">",
"      Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Relation of pulmonary vein to mitral flow velocities by transesophageal Doppler echocardiography. Effect of different loading conditions. Circulation 1990; 81:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/16\">",
"      Kuecherer HF, Muhiudeen IA, Kusumoto FM, et al. Estimation of mean left atrial pressure from transesophageal pulsed Doppler echocardiography of pulmonary venous flow. Circulation 1990; 82:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/17\">",
"      Kuecherer HF, Kusumoto F, Muhiudeen IA, et al. Pulmonary venous flow patterns by transesophageal pulsed Doppler echocardiography: relation to parameters of left ventricular systolic and diastolic function. Am Heart J 1991; 122:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/18\">",
"      Rossvoll O, Hatle LK. Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures. J Am Coll Cardiol 1993; 21:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/19\">",
"      Klein AL, Stewart WJ, Bartlett J, et al. Effects of mitral regurgitation on pulmonary venous flow and left atrial pressure: an intraoperative transesophageal echocardiographic study. J Am Coll Cardiol 1992; 20:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18054/abstract/20\">",
"      Kusumoto FM, Muhiudeen IA, Kuecherer HF, et al. Response of the interatrial septum to transatrial pressure gradients and its potential for predicting pulmonary capillary wedge pressure: an intraoperative study using transesophageal echocardiography in patients during mechanical ventilation. J Am Coll Cardiol 1993; 21:721.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5296 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18054=[""].join("\n");
var outline_f17_40_18054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15996275\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15996268\">",
"      HEMODYNAMIC VARIABLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Left ventricular and atrial filling pressures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Doppler mitral inflow velocity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pulmonary venous flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mitral regurgitation continuous-wave Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Left ventricular and atrial chamber sizes (preload)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypervolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intra-atrial septal motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15996275\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5296|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/35/17970\" title=\"diagnostic image 1\">",
"      CW Doppler pulmonary vein MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/57/34704\" title=\"diagnostic image 2\">",
"      Doppler pulmonary vein MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5296|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/8/38029\" title=\"figure 1\">",
"      Pulmonary vein velocity schematic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/1/27671\" title=\"figure 2\">",
"      Pulsed wave Doppler pulmonary venous flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5296|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/33/28177\" title=\"waveform 1A\">",
"      LV Doppler flow patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/31/5618\" title=\"waveform 1B\">",
"      Doppler transmitral inflow pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/45/32470\" title=\"waveform 2\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42040?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13240?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of the left ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=related_link\">",
"      Transesophageal echocardiography: Indications, complications, and normal views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_40_18055="Candida infections of the abdomen and thorax";
var content_f17_40_18055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Candida infections of the abdomen and thorax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18055/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18055/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18055/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18055/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18055/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/40/18055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of infection with Candida species range from local mucous membrane infections to widespread dissemination with multisystem organ failure. Although Candida are considered normal flora in the gastrointestinal and genitourinary tracts of humans, they have the propensity to invade and cause disease when an imbalance is created in the ecologic niche in which these organisms usually exist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=see_link\">",
"     \"Biology of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immune response of the host is an important determinant of the type of infection caused by Candida. The different Candida species generally are capable of producing all of the clinical syndromes, although infection with Candida albicans is the most common. The major importance of identifying the infecting organism is that some species are more resistant to the azole antifungal agents than others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the manifestations of Candida infection involving the abdomen and thorax. Other manifestations of Candida infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=see_link\">",
"     \"Overview of Candida infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERITONITIS AND INTRAABDOMINAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species frequently contribute to polymicrobial infections that occur following gut perforation, anastomotic leaks after bowel surgery, and acute necrotizing pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Discrete abscesses with or without peritonitis can occur.",
"   </p>",
"   <p>",
"    Candida peritonitis can also complicate continuous peritoneal dialysis in patients with end-stage renal disease. This disorder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other intraabdominal manifestations of Candida infection include isolated pancreatic abscess, gangrenous cholecystitis, and obstruction to the common bile duct with a Candida fungus ball [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. C. albicans is the predominant species isolated in intraabdominal candidal infections, but C. glabrata has assumed an increasing role at some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms of Candida peritonitis do not differ from those of bacterial peritonitis, which also is often present. Fevers, chills, and abdominal pain are prominent. Complications include abscess formation and bloodstream invasion with sepsis.",
"   </p>",
"   <p>",
"    The diagnosis is best made by aspiration of fluid under computed tomographic (CT) or ultrasound guidance or at the time of surgery. Growth of Candida species from an abscess or peritoneal fluid is adequate for the diagnosis of invasive intraabdominal candidiasis and should lead to appropriate treatment with an antifungal agent. Culture of Candida species from an indwelling drain is not adequate for the diagnosis of infection because it often reflects only colonization of the drain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of intraabdominal candidiasis usually entails both surgical intervention and antifungal therapy. Surgical management involves drainage of abscesses and relief of biliary tract obstruction. Depending on the location of the abscess, drainage can often be performed by an interventional radiologist, obviating the need for a laparotomy. Initial antifungal therapy is similar to that for candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    loading dose, then 400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) is usually given, but an echinocandin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , 100 mg intravenously daily;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , 200 mg loading dose, then 100 mg intravenously daily; or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , 70 mg loading dose, then 50 mg intravenously daily) is a better choice if C. glabrata is the likely species (",
"    <a class=\"graphic graphic_table graphicRef87676 \" href=\"UTD.htm?9/28/9677\">",
"     table 1",
"    </a>",
"    ). A lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) or amphotericin B deoxycholate (0.6 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) are alternatives, but are used infrequently because of the greater toxicity of amphotericin B.",
"   </p>",
"   <p>",
"    Following identification of the infecting species, treatment can be modified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For susceptible species, such as C. albicans, C. parapsilosis, and C. tropicalis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      is preferred. The concentrations of fluconazole achieved in bile are as high or higher than levels achieved in serum [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/7\">",
"       7",
"      </a>",
"      ], and excellent concentrations are achieved in peritoneal fluid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"       \"Pharmacology of azoles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When C. glabrata is the cause of infection, the preferred agent is an echinocandin.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      also has been approved for the treatment of Candida intraabdominal infections and can be used for oral step-down therapy after initial intravenous echinocandin therapy. Susceptibilities should be obtained before using voriconazole for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant isolates because of possible cross-resistance with fluconazole. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the infecting organism is C. parapsilosis, an echinocandin should not be used because of the relatively high MICs for echinocandins with this organism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. parapsilosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy should continue for at least two weeks and often longer, until the abscess and all signs and symptoms of peritonitis are resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary pneumonia due to Candida species is extremely rare. The pathogenesis of lung involvement is that of hematogenous spread, rather than aspiration of oropharyngeal secretions. Thus, multiple microabscesses are found scattered widely throughout the lung parenchyma, and lobar infiltrates are uncommon. Autopsy studies from cancer centers have documented that primary Candida pneumonia, in which infection is limited to the lungs, occurs in less than 1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Much more commonly, the lungs are one of many organs involved in the course of disseminated infection with Candida in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a review of a 20 year experience from the MD Anderson Cancer Center, there were only 55 cases of clearly documented primary Candida pneumonia in cancer patients found at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 17 hematopoietic stem cell transplant recipients who had histologically-proven pulmonary candidiasis, the CT findings included multiple nodules ranging from 3 to 30 mm in diameter in 15 patients. Air-space consolidation was present in 11 patients and in five, nodules were surrounded by discrete areas of ground-glass opacity (CT halo sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Studies in both cancer patients and non-neutropenic patients in an ICU setting have confirmed the lack of specificity of sputum or bronchoalveolar lavage specimens for the diagnosis of pulmonary invasion by Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ]. Among 36 cancer patients with autopsy evidence of Candida pneumonia in whom sputum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoalveolar lavage (BAL) were performed &le;4 weeks before death the sensitivity and specificity was found to be 85 and 60 percent for sputum culture and 71 and 57 percent for bronchoalveolar lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 232 intensive care unit (ICU) patients who died with pneumonia and underwent autopsy, none of 77 patients with Candida spp isolated from a tracheal aspirate or bronchoalveolar lavage fluid had histopathologic evidence of Candida pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/16\">",
"     16",
"    </a>",
"    ]. Similarly, in a study of 1077 BAL specimens obtained from 555 mechanically ventilated patients in an intensive care unit, only 8 percent yielded Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/15\">",
"     15",
"    </a>",
"    ]. Of these 85 samples, 92 percent were judged to reflect colonization only. Only two patients were treated for presumed Candida pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is not recommended for Candida isolated from sputum or BAL specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with disseminated candidiasis who develop secondary Candida pneumonia should be treated for disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EMPYEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest reported experience of Candida empyema comes from a retrospective study of 67 cases of fungal empyema, all but nine of which grew Candida species (mostly C. albicans and C. glabrata) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/17\">",
"     17",
"    </a>",
"    ]. An underlying predisposing condition was present in 85 percent, with malignancy as the leading underlying disease. Most of the cases were nosocomially acquired and 27 percent had underlying fungemia. Bacterial pathogens were also isolated in approximately one-fourth of the cultures.",
"   </p>",
"   <p>",
"    There were two criteria for diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation of a fungal species from a pleural effusion that was classified as an exudate AND",
"     </li>",
"     <li>",
"      Clinical signs of infection such as fever and leukocytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients were treated with an antifungal agent and closed drainage. The overall mortality rate was 73 percent, in part because most patients had severe underlying illnesses. A multivariate analysis demonstrated that compromised immunity, lack of antifungal therapy, and respiratory failure were significantly associated with the risk of death. Systemic administration of all available antifungal agents most likely results in appropriate levels in the pleural fluid, but data in this area are scarce.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most appropriate agent is oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    loading dose, then 400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily) if the organism is susceptible.",
"   </p>",
"   <p>",
"    For C. glabrata, an echinocandin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , 100 mg intravenously daily;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , 200 mg loading dose, then 100 mg intravenously daily; or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , 70 mg loading dose, then 50 mg intravenously daily) is suggested for initial therapy. After a week or two, therapy can be changed from an echinocandin to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (400 mg twice daily for two doses, then 200 mg twice daily) if the organism is shown to be susceptible.",
"   </p>",
"   <p>",
"    The duration of antifungal therapy varies with the reasons for the development of empyema and the response to drainage procedures. A minimum of two weeks of antifungal therapy after the chest tube is removed or after a decortication procedure is performed may be enough, but for other patients a longer treatment course may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEDIASTINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida mediastinitis almost always occurs after thoracic surgery procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. In a report of nine cases of Candida mediastinitis, the primary clinical manifestations included chest wall erythema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage, fever, and sternal instability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/18\">",
"     18",
"    </a>",
"    ]. These findings are similar to those seen with bacterial causes of postoperative mediastinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients had received prior antibiotic therapy and the median time from surgery to disease onset was 11 days (range 6 to 100 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/18\">",
"     18",
"    </a>",
"    ]. The course was complicated in seven patients by contiguous or hematogenous spread. The diagnosis was delayed in three patients because intraoperative cultures were not obtained or cultures positive for Candida were considered contaminants.",
"   </p>",
"   <p>",
"    In this study and an earlier review of 39 published cases of Candida mediastinitis, the mortality rate was 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. In the latter report, no patient survived without undergoing a mediastinal drainage procedure compared with survival in 11 of 13 patients (85 percent) who underwent mediastinal drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal drainage with debridement of affected bone in combination with antifungal therapy is essential for cure. The choice of agent should be similar to that recommended for candidemia. Thus, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    loading dose, then 400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily), for susceptible species, or an echinocandin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    ,100 mg intravenously daily;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , 200 mg loading dose, then 100 mg intravenously daily; or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , 70 mg loading dose, then 50 mg intravenously daily) is recommended (",
"    <a class=\"graphic graphic_table graphicRef87676 \" href=\"UTD.htm?9/28/9677\">",
"     table 1",
"    </a>",
"    ). A lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) or amphotericin B deoxycholate (0.6 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) are alternatives. Therapy is prolonged in most cases and only stopped when all clinical and laboratory signs of infection have resolved.",
"   </p>",
"   <p>",
"    In many cases, sternal osteomyelitis accompanies mediastinal infection, which requires prolonged therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for susceptible species. For patients who have C. glabrata mediastinitis and perhaps osteomyelitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is the most appropriate agent for long-term oral therapy provided that the isolate is susceptible (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    ). If sternal involvement is present, the duration of therapy may extend to six months or longer. Clinical response, improvement in inflammatory markers (erythrocyte sedimentation rate, C-reactive protein), and resolution of CT scan findings are the usual parameters that help determine length of oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purulent pericarditis due to Candida species is rare, but life-threatening. It most often arises as a complication of previous thoracic surgery or contiguous spread from an adjacent focus, but hematogenous spread can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. C. albicans is the most common pathogen, but infection with C. tropicalis and C. glabrata has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a literature review of 25 cases, 21 had either undergone thoracic surgery or had disseminated candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/23\">",
"     23",
"    </a>",
"    ]. Immunocompromise and antibiotic therapy are other risk factors, as they are for almost all Candida infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of Candida infections\", section on 'Risk factors for invasive infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation may be subtle and nonspecific in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/22\">",
"     22",
"    </a>",
"    ], but other patients will present with an enlarging cardiac shadow on chest radiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of cardiac tamponade. The diagnosis is confirmed by a positive culture of pericardial fluid or yeast forms on pericardial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated Candida pericarditis is almost uniformly fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Tamponade must be treated emergently with decompression and subsequently with a pericardial window or pericardiectomy to prevent recurrent hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/9,22-25\">",
"     9,22-25",
"    </a>",
"    ]. Although not recommended, occasional patients have survived with only pericardiocentesis and antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    loading dose, then 400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) or an echinocandin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , 100 mg intravenously daily;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , 200 mg loading dose, then 100 mg intravenously daily; or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , 70 mg loading dose, then 50 mg intravenously daily) is recommended (",
"    <a class=\"graphic graphic_table graphicRef87681 \" href=\"UTD.htm?38/10/39084\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18055/abstract/9\">",
"     9",
"    </a>",
"    ]. A lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) or amphotericin B deoxycholate (0.6 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) are alternatives. Patients receiving amphotericin B or an echinocandin can be switched to oral fluconazole (400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily) when they are clinically stable.",
"   </p>",
"   <p>",
"    For pericarditis due to C. glabrata, echinocandin therapy followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (400 mg orally twice daily for two doses, then 200 mg twice daily) is an option. Susceptibilities should be obtained before using voriconazole for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant isolates because of possible cross-resistance with fluconazole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal length of therapy required is not known. The patient should be followed clinically and therapy stopped only when there are no signs of ongoing pericardial inflammation and all systemic signs of infection, such as an elevated erythrocyte sedimentation rate and anemia, have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25389396\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida species frequently contribute to polymicrobial infections that occur following gut perforation, anastomotic leaks after bowel surgery, and acute necrotizing pancreatitis. Discrete abscesses with or without peritonitis can occur. Candida peritonitis can also complicate continuous peritoneal dialysis in patients with end-stage renal disease.",
"     </li>",
"     <li>",
"      Other intraabdominal manifestations of Candida infection include isolated pancreatic abscess, gangrenous cholecystitis, and obstruction of the common bile duct with a Candida fungus ball. C. albicans is the predominant species isolated in intraabdominal candidal infections, but C. glabrata has assumed an increasing role at some centers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Peritonitis and intraabdominal infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth of Candida species from an abscess or peritoneal fluid is adequate for the diagnosis of invasive intraabdominal candidiasis and should lead to appropriate treatment with an antifungal agent. Culture of Candida species from an indwelling drain is not adequate for the diagnosis of infection because it often reflects only colonization of the drain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Peritonitis and intraabdominal infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When treatment is indicated as noted below, the following dosages should be used:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      (800 mg [12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      loading dose, then 400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily, depending on the indication)",
"     </li>",
"     <li>",
"      Echinocandins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      , 100 mg intravenously daily;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      , 200 mg loading dose, then 100 mg intravenously daily; or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      , 70 mg loading dose, then 50 mg intravenously daily)",
"     </li>",
"     <li>",
"      Lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily) or amphotericin B deoxycholate (0.6 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily)",
"      <br/>",
"      <br/>",
"      Patients receiving amphotericin B or an echinocandin can usually be switched to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily) if the isolate is susceptible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of intraabdominal candidiasis usually entails both surgical intervention and antifungal therapy. The choice of agent depends upon the Candida species. Surgical management involves drainage of abscesses and relief of biliary tract obstruction.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      or an echinocandin is recommended (",
"      <a class=\"graphic graphic_table graphicRef87676 \" href=\"UTD.htm?9/28/9677\">",
"       table 1",
"      </a>",
"      ). A lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or a lipid formulation amphotericin B deoxycholate are alternatives that are used infrequently because of their greater toxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary pneumonia due to Candida species is extremely rare. The pathogenesis of lung involvement is that of hematogenous spread, rather than aspiration of oropharyngeal secretions. Thus, multiple microabscesses are found scattered widely throughout the lung parenchyma, and lobar infiltrates are uncommon. Treatment is not recommended for Candida isolated from sputum or BAL specimens. Patients with disseminated candidiasis who develop secondary Candida pneumonia should be treated for disseminated disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candida empyema occurs most commonly in individuals with underlying conditions such as malignancy, and in hospitalized patients. The most appropriate agent is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      if the organism is susceptible. For C. glabrata, an echinocandin is suggested for initial therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Empyema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candida mediastinitis almost always occurs after thoracic surgery procedures. Mediastinal drainage with debridement of affected bone in combination with antifungal therapy is essential for cure. The choice of agent should be similar to that recommended for candidemia. Thus, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , for susceptible species, or an echinocandin is recommended. A lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or amphotericin B deoxycholate are less frequently used alternatives. Therapy is prolonged in most cases and only stopped when all clinical and laboratory signs of infection have resolved. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mediastinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Purulent pericarditis due to Candida species is rare, but life-threatening. It most often arises as a complication of previous thoracic surgery or contiguous spread from an adjacent focus, but hematogenous spread can occur. Therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      or an echinocandin is recommended (",
"      <a class=\"graphic graphic_table graphicRef87681 \" href=\"UTD.htm?38/10/39084\">",
"       table 2",
"      </a>",
"      ). A lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or a lipid formulation of amphotericin B deoxycholate are alternatives. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/1\">",
"      Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/2\">",
"      Sandven P, Qvist H, Skovlund E, et al. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/3\">",
"      Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999; 188:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/4\">",
"      Hoerauf A, Hammer S, M&uuml;ller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998; 26:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/5\">",
"      Keiser P, Keay S. Candidal pancreatic abscesses: report of two cases and review. Clin Infect Dis 1992; 14:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/6\">",
"      Morris AB, Sands ML, Shiraki M, et al. Gallbladder and biliary tract candidiasis: nine cases and review. Rev Infect Dis 1990; 12:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/7\">",
"      Bozzette SA, Gordon RL, Yen A, et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin Infect Dis 1992; 15:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/8\">",
"      Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/9\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/10\">",
"      Haron E, Vartivarian S, Anaissie E, et al. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993; 72:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/11\">",
"      Kontoyiannis DP, Reddy BT, Torres HA, et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/12\">",
"      Franquet T, M&uuml;ller NL, Lee KS, et al. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology 2005; 236:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/13\">",
"      Rello J, Esandi ME, D&iacute;az E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/14\">",
"      el-Ebiary M, Torres A, F&agrave;bregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/15\">",
"      Wood GC, Mueller EW, Croce MA, et al. Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 2006; 32:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/16\">",
"      Meersseman W, Lagrou K, Spriet I, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/17\">",
"      Ko SC, Chen KY, Hsueh PR, et al. Fungal empyema thoracis: an emerging clinical entity. Chest 2000; 117:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/18\">",
"      Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: an emerging clinical entity. Clin Infect Dis 1997; 25:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/19\">",
"      Malani PN, McNeil SA, Bradley SF, Kauffman CA. Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy. Clin Infect Dis 2002; 35:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/20\">",
"      Glower DD, Douglas JM Jr, Gaynor JW, et al. Candida mediastinitis after a cardiac operation. Ann Thorac Surg 1990; 49:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/21\">",
"      Pertowski CA, Baron RC, Lasker BA, et al. Nosocomial outbreak of Candida albicans sternal wound infections following cardiac surgery traced to a scrub nurse. J Infect Dis 1995; 172:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/22\">",
"      Rabinovici R, Szewczyk D, Ovadia P, et al. Candida pericarditis: clinical profile and treatment. Ann Thorac Surg 1997; 63:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/23\">",
"      Schrank JH Jr, Dooley DP. Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis 1995; 21:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/24\">",
"      Neughebauer B, Alvarez V, Harb T, Keefer M. Constrictive pericarditis caused by candida glabrata in an immunocompetent patient: case report and review of literature. Scand J Infect Dis 2002; 34:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/25\">",
"      Chaudhary K, Faidas A, Baddour LM. Candida pericarditis: unusual complication following hiatal hernia repair. Infect Dis Clin Pract 1996; 5:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18055/abstract/26\">",
"      Karp R, Meldahl R, McCabe R. Candida albicans purulent pericarditis treated successfully without surgical drainage. Chest 1992; 102:953.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2436 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18055=[""].join("\n");
var outline_f17_40_18055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25389396\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERITONITIS AND INTRAABDOMINAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EMPYEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEDIASTINITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25389396\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2436|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/28/9677\" title=\"table 1\">",
"      Treatment of candidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/10/39084\" title=\"table 2\">",
"      Treatment of Candida cardiovascular infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=related_link\">",
"      Biology of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_40_18056="Iron overload liver Light";
var content_f17_40_18056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biopsy in hereditary hemochromatosis (H and E staining)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a liver biopsy from a patient with hereditary hemochromatosis showing brown pigmentation of hepatocytes due to iron deposition (hematoxylin and eosin stain). The presence of iron can be confirmed by Perls' Prussian blue stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18056=[""].join("\n");
var outline_f17_40_18056=null;
var title_f17_40_18057="Myotonic dystrophy: Prognosis and management";
var content_f17_40_18057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myotonic dystrophy: Prognosis and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18057/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18057/contributors\">",
"     David A Chad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18057/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18057/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18057/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18057/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/40/18057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are autosomal dominant, multisystem disorders characterized by skeletal muscle weakness and myotonia, cardiac conduction abnormalities, and iridescent cataracts. Immune and endocrine manifestations of myotonic dystrophy include hypogammaglobulinemia, testicular failure, and insulin resistance (insensitivity).",
"   </p>",
"   <p>",
"    DM1 results from an unstable CTG repeat expansion in the DMPK gene on chromosome 19, and DM2 is caused by the expansion of a CCTG repeat of the ZNF9 gene on chromosome 3; in both diseases, the multisystem features are caused by corresponding CUG (DM1) and CCUG (DM2) expansions expressed at the RNA level [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, DM2 is a less severe disease than DM1. There are congenital, juvenile, and adult onset forms of DM1, whereas only an adult onset form of DM2 is recognized. Typically, DM1 patients come to medical attention because of mental retardation or severe muscle weakness and myotonia, whereas in DM2, the chief complaints are usually muscle pain, stiffness, fatigue, or proximal muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no disease-modifying therapy available for the treatment of myotonic dystrophy. Thus, treatment is symptomatic. The systemic (non-neuromuscular) manifestations of myotonic dystrophy are the most treatable aspects of the disease. Recommendations regarding management are based more on consensus and clinical experience than on evidence from randomized controlled trials.",
"   </p>",
"   <p>",
"    The management and prognosis of patients with myotonic dystrophy will be reviewed here. Other aspects of myotonic dystrophy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although evidence is limited, life expectancy appears to be reduced for patients with DM1 of childhood or adult onset [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Respiratory and cardiac diseases are the most common causes of death. Younger age of onset, more severe muscle weakness, and cardiac arrhythmia may be associated with an increased risk of death.",
"   </p>",
"   <p>",
"    These points are illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longitudinal cohort study of 367 patients with DM1 with a median age of 33 (range 2 to 80) at baseline were followed for 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/2\">",
"       2",
"      </a>",
"      ]. During the course of the study, 75 patients (20 percent) died. The main causes of death were pneumonia (43 percent), cardiovascular disease or sudden death (31 percent), and neoplasia (8 percent). The overall mean age at death was 53 years. Using age-matched general population mortality rates as a comparator, the standardized mortality ratio (a ratio of observed to expected deaths) for those with myotonic dystrophy was significantly increased to 7.3 (95 percent CI 5.8&ndash;9.1).",
"     </li>",
"     <li>",
"      In another longitudinal study of 408 patients with DM1 who were followed for a mean of 5.7 years, there were 81 deaths (20 percent), and the mean age at death was 54 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/4\">",
"       4",
"      </a>",
"      ]. The most common cause of death, affecting 32 of 81 patients (40 percent), was progressive neuromuscular respiratory failure. Twenty-seven patients (33 percent) died suddenly. Independent risk factors for sudden death were severe conduction system abnormality on baseline ECG (relative risk [RR] 3.3, 95% CI 1.24-8.78) and a clinical diagnosis of atrial tachyarrhythmia (RR 5.18, 95% CI 2.28-11.77). Independent risk factors for death from progressive neuromuscular respiratory failure were patient age, severe proximal muscle weakness, heart failure, and atrial tachyarrhythmia.",
"     </li>",
"     <li>",
"      Cardiac conduction disturbances can progress rapidly and are associated with mortality in DM. In a cohort of 30 patients with DM1 who were followed over a 17-year period, the baseline ECG sum of the PR interval plus QRS duration of &ge;320 msec was the best predictor of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/5\">",
"       5",
"      </a>",
"      ]. All survivors had a PR plus QRS time of &lt;320 msec. However, among the 15 patients who died, the cause was respiratory in 10 and cardiac in 3. In another study of 70 patients with DM1, independent positive predictors of PR and QRS prolongation during long-term follow-up were paroxysmal atrial flutter or fibrillation, older age and larger CTG repeat expansions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 115 patients with the congenital form of DM1, life-table data suggested that the chance of death before 18 months of age was 25 percent, while the chance of survival into the mid-thirties was 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/7\">",
"       7",
"      </a>",
"      ]. Up to 20 percent of patients died either suddenly or of documented cardiac arrhythmias.",
"     </li>",
"     <li>",
"      In a retrospective report, cardiac sudden death before age 45 occurred in four patients with DM2, including three with no symptoms of heart disease, and one with a history of heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/8\">",
"       8",
"      </a>",
"      ]. On histopathology, all four patients had a dilated cardiomyopathy, and two had conduction system fibrosis.",
"     </li>",
"     <li>",
"      In a prospective multicenter study of 406 adult patients with DM1 (age &ge;18 years, 15 percent with congenital or childhood-onset) who were followed for a mean of nine years, there was an inverse relationship between survival and CTG repeat length, supporting a genotype-mortality association in DM1 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/9\">",
"       9",
"      </a>",
"      ]. The mean age at death was 54 years, which is similar to that found in other cohorts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with congenital DM1, mental and behavioral disturbances are additional factors that influence long-term management and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue that contributes to reduced life expectancy and increased morbidity is a tendency for medical care to be fragmented or deficient for DM1 patients and families. This phenomenon may result from two main factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The complex manifestations of DM1, including neuromuscular, behavioral, emotional, and cognitive disturbances, contribute to suboptimal education levels, employment problems, and diminished income when compared with the general population, and accordingly compromise the daily activities and social roles of patients with this disease.",
"     </li>",
"     <li>",
"      The variable multisystem presentations and complications of DM1 pose diagnostic and management challenges for the medical community.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the disease is multifaceted and variable, its management requires an interdisciplinary approach among health professionals, and involves many different skills and services from community resources [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     DM2 prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the DM2 population, the absence of a congenital form, the lack of association with any developmental abnormalities or severe childhood symptoms, and the relatively mild extramuscular manifestations (compared with DM1) suggest that life expectancy is unlikely to be compromised to the extent that it may be in patients with classic DM1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of DM1 is that of gradual progression in weakness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that followed 50 patients aged 16 to 67 years with DM1, muscle weakness at baseline was symmetrical, with neck flexor and distal muscles weaker than proximal muscle groups [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/12\">",
"       12",
"      </a>",
"      ]. Using manual muscle testing, the average strength decline was approximately 1 percent per year, similar for men and women, and more rapid for distal than proximal muscles (2 to 3 percent for hand grip flexors and 1.2 to 1.6 percent per year for hip flexors).",
"     </li>",
"     <li>",
"      In a series of 158 patients with DM1 who had assessment of finger flexor muscle strength using a hand-held dynamometer, strength diminished at a rate of 1.18",
"      <span class=\"nowrap\">",
"       kgN/year",
"      </span>",
"      for women and 1.61",
"      <span class=\"nowrap\">",
"       kgN/year",
"      </span>",
"      for men [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the disease progresses, distal muscles become increasingly weak, and proximal muscles, perhaps spared in the early stages, begin to weaken so that gait and stability slowly deteriorate. Thus, patients with DM1 develop a combination of distal and proximal weakness (foot dorsiflexor weakness, along with knee extensor and hip abductor and flexor weakness) that contributes to an increased incidence of falls. This point is illustrated by the finding that falls and stumbles in patients with DM1 are 10 times more frequent than in a group of healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of physical disability depends on the distribution and severity of muscle weakness and is best provided by a multidisciplinary team including neurologists, physiatrists, and occupational and physical therapists.",
"   </p>",
"   <p>",
"    Initially, molded ankle-foot orthoses are helpful in preventing foot-drop and enhancing gait stability. Over time, patients may find that a walker is necessary to navigate distances with confidence and safety, and in the later stages of the illness, a wheelchair may be required, especially for longer distances outside of the home.",
"   </p>",
"   <p>",
"    Accordingly, the sequential and often combined use of ankle-foot orthoses, walkers, and wheelchairs in concert with multidisciplinary interventions (addressing the compromised vision, fatigue, and visuospatial deficits of patients with DM1) are important in maintaining health and safety in these patients.",
"   </p>",
"   <p>",
"    Neck muscle weakness is common in DM1, affecting both flexor and extensor groups, and tends to cause head-drop; this symptom may be ameliorated by a fitted collar. Eye lid crutches or blepharoplasty may be helpful for troublesome ptosis encountered in DM1.",
"   </p>",
"   <p>",
"    In DM2, progression and severity of weakness are less pronounced that in DM1. When necessary, the assistive devices described for DM1 are likely to be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muscle pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In DM2, muscle pain can be a persistent and troubling symptom. Pharmacologic agents that may be effective for this problem include nonsteroidal anti-inflammatory drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    , and low-dose glucocorticoids, such as oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    5 mg on alternate days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/15\">",
"     15",
"    </a>",
"    ]. We begin management with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    as needed, along with gabapentin up to 300 mg three times per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exercise training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate-intensity strength training for myotonic dystrophy (DM1) has been assessed in one small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/16\">",
"     16",
"    </a>",
"    ]. There was no clear evidence of benefit or harm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A smaller study on the effects of aerobic training in 12 patients with DM1 for 12 weeks on a cycle ergometer noted that patients increased maximal oxygen uptake by 14 percent, and increased maximal workload by 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/18\">",
"     18",
"    </a>",
"    ]. However 5 of 17 patients who were originally enrolled dropped out of the study because of low compliance and 3 of the 12 who completed the study did not follow the original training schedule. Thus, such approaches to fitness are likely to be most appropriate for a relatively small subset of patients with DM1 who exercise under supervision.",
"   </p>",
"   <p>",
"    In the absence of evidence that exercise is effective for improving muscle strength, we suggest that patients with myotonic dystrophy engage in low intensity exercise, to the extent that they are capable and without undue physical stress. We also suggest that exercise include gentle stretching actions at selected joints, such as dorsiflexion at the ankles, extension at the knees, and abduction at the hips, which may attenuate the tendency for tendon shortening and joint contractures. This recommendation is based upon the intuitive sense that stretching and exercise may be systemically beneficial, and upon evidence that low intensity exercise is not harmful.",
"   </p>",
"   <p>",
"    Since exercise can precipitate serious arrhythmias, some have suggested exercise testing with electrocardiographic (ECG) monitoring as part of the routine evaluation of young patients with myotonic dystrophy type 1 (DM1) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/19\">",
"     19",
"    </a>",
"    ]. We suggest exercise testing with electrocardiographic (ECG) monitoring prior to beginning an exercise training program in patients with cardiac symptoms or an abnormal baseline ECG. In this group of patients, a decision regarding the safety of exercise training should be made by a cardiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk of statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether patients with DM1 and DM2 receiving statins are at increased risk of worsening myopathic symptoms and signs is not known. However, statins have well-known myopathic side effects that occur in up to 7 percent of treated patients in the general population; these include pain, raised creatinine kinase, and myoglobinuria (rarely). In addition, it has been observed that individuals with metabolic muscle disorders are more likely to experience statin-induced myopathic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/20\">",
"     20",
"    </a>",
"    ]. Therefore, a cautious approach seems warranted in patients with myotonic dystrophy",
"   </p>",
"   <p>",
"    We suggest that patients with DM1 and DM2 on statins should have close monitoring of statin dose, potential myopathic symptoms, and serum creatinine kinase levels. Statin use should be abandoned in favor of another lipid management strategy if an increase in statin-related muscle symptoms and signs develop. Of note, statin-induced muscle symptoms may be difficult to distinguish from the muscle pain associated with DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RESPIRATORY FUNCTION AND SLEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory complications and sleep-related breathing abnormalities are common in DM1 but are less frequent and severe in DM2. These problems are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H12#H12\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Respiratory function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accordingly, an important aspect of respiratory management in DM1 is to gauge effectiveness of gas exchange by clinical signs (comfort level, respiratory rate, oxygen saturation, auscultation for air entry into the lung bases) and observation for and evidence of diaphragmatic paralysis and pneumonia.",
"   </p>",
"   <p>",
"    In adults with DM1, we often follow up the clinical assessment by obtaining forced vital capacity (FVC) measurements, and use the values of serial FVC results in concert with clinical findings to follow respiratory status. In the absence of data upon which to base specific recommendations, we suggest that FVC be measured annually in asymptomatic adult subjects but more regularly in those with dyspnea or previously documented reduction in FVC.",
"   </p>",
"   <p>",
"    In patients demonstrated to have alveolar hypoventilation, regular use of incentive spirometry and a cough assist device may help to counteract the tendency for atelectasis and hypercarbia and reduce the risk of pneumonia.",
"   </p>",
"   <p>",
"    It is also critical to assess the quality of sleep in patients with DM1, probing for whether there is nocturnal restlessness, unexplained awakenings, and loud snoring punctuated by occasional awakenings and gasping for breath, all of which should suggest the presence of a sleep-related respiratory disorder and lead to further study with a polysomnographic evaluation that will reveal a more specific diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninvasive positive airway pressure ventilation (NIPPV) may be very helpful in correcting sleep apnea, improving hypoventilation, and assisting diaphragm weakness. Bilevel positive airway pressure ventilation (BiPAP) is better tolerated by patients with weakness of the chest wall and diaphragm who cannot overcome expiratory forces. NIPPV may also be used symptomatically during the day to rest weak respiratory muscles and to improve dyspnea. In rare instances, the progressive loss of respiratory drive and the increasing severity of diaphragm and chest wall muscle weakness creates a situation in which NIPPV no longer provides adequate respiratory support and tracheostomy may be considered.",
"   </p>",
"   <p>",
"    Children with juvenile myotonic dystrophy may not be able to cooperate for reliable pulmonary function testing. However, most adolescent patients can be tested, and a baseline FVC and forced expiratory volume in one second (FEV1) measurement is suggested for adolescent patients. Periodic testing is not needed for most pediatric patients with DM1, but we suggest annual or biannual pulmonary tests in adolescents with dyspnea or reduced baseline FVC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    FEV1 values. We also suggest pulmonary function tests as part of preoperative evaluation if general anesthesia is anticipated. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Risk of anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infants with congenital DM1 often require continuous ventilatory support. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Congenital myotonic dystrophy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DYSPHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swallowing assessment is an important part of the management of patients with DM1, as dysphagia is a risk factor for aspiration pneumonia and poor nutrition. In juvenile DM1 in particular, dysphagia may lead to poor weight gain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the major problems faced by patients with DM1 is fatigue, which in turn leads to reduced nutritional intake. Advice to eat smaller meals more frequently may help to overcome the problem of fatigue.",
"     </li>",
"     <li>",
"      Problems with aspiration may be managed by modifying the consistency of foods, which is mostly accomplished by thickening of liquids, as well as by sleeping with the head of the bed elevated.",
"     </li>",
"     <li>",
"      Pharyngeal muscle myotonia, sometimes triggered by cold liquids, may impair swallowing and might be relieved by avoiding cold liquids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Formal evaluation by a speech and swallow therapist is appropriate for those with symptomatic dysphagia, and referral to a nutritionist may be useful for advice regarding calorie supplementation.",
"   </p>",
"   <p>",
"    Assessment by gastroenterology specialists may also be helpful for some adult or pediatric patients with dysphagia. Intestinal pseudoobstruction has been reported in patients with myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/23\">",
"     23",
"    </a>",
"    ]; it may be severe enough to require either a temporary or permanent ileostomy.",
"   </p>",
"   <p>",
"    Similarly, children with congenital DM1 are at increased risk for aspiration and may benefit from a feeding evaluation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Congenital myotonic dystrophy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Lip strengthening exercises can increase maximal lip force and endurance but do not improve dysarthria, saliva control, or eating and drinking ability in children and adolescents with DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/24\">",
"     24",
"    </a>",
"    ]. They can complement speech and dysphagia therapies but cannot replace them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CARDIAC CONDUCTION DISTURBANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac conduction disturbances and tachyarrhythmias occur in DM1, and to a lesser extent in DM2. In some instances, cardiac arrhythmias may occur as a very early manifestation of the disease. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H9#H9\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Cardiac abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A careful cardiac history (seeking evidence for palpitations, blackouts, syncope, and dyspnea), examination (ascertainment for bradyarrhythmia, ectopic beats, mitral valve prolapse, and atrial fibrillation), and standard 12 lead ECG should be done at least yearly for patients with DM1 and DM2. We suggest 24-hour ambulatory ECG monitoring when arrhythmias are suspected clinically but are not detected on standard ECG. In addition, we suggest echocardiography if symptoms or signs raise suspicion for myocardial dysfunction.",
"   </p>",
"   <p>",
"    We typically refer our patients to a cardiologist for ongoing care and follow-up in parallel with neurology clinic visits.",
"   </p>",
"   <p>",
"    The indications for pacemaker placement remain controversial, primarily because available data are limited. The largest study was a retrospective analysis of 486 adults from the DM1 Heart Registry who had a PR interval &gt;200 msec or a QRS duration &gt;100 msec or both [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/25\">",
"     25",
"    </a>",
"    ]. The study compared 341 patients who were treated with an invasive strategy (electrophysiologic study and permanent pacemaker if the HV interval was &gt;70 msec) with 145 patients who had noninvasive management. In the unadjusted analysis, there was a trend toward longer nine-year survival in the invasive compared with the noninvasive group (77 versus 70 percent), but the difference was not statistically significant (hazard ratio [HR] 0.74, 95% CI 0.47-1.16). However, in several different analyses that adjusted for between-group differences in baseline characteristics, the longer survival associated with the invasive strategy was statistically significant, with adjusted HRs ranging from 0.47 (95% CI 0.26-0.84) to 0.61 (95% CI 0.38-0.99). This finding was mainly due to a significantly lower incidence of sudden death associated with the invasive strategy.",
"   </p>",
"   <p>",
"    Guidelines from the American College of Cardiology and American Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    recommend pacemaker placement for third-degree or advanced second degree atrioventricular (AV) block in patients with myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H23#H23\">",
"     \"Indications for permanent cardiac pacing\", section on 'Neuromuscular diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines also recommend consideration of pacemaker placement for patients with myotonic dystrophy who have any degree of AV block (including first degree AV block), even if asymptomatic, based upon a concern that there may be unpredictable progression of AV conduction disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines do not cite primary data to support the claim that there may be unpredictable progression of AV conduction disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Congenital myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with congenital myotonic dystrophy type 1 (DM1) often present with respiratory and feeding difficulties and may require continuous ventilatory support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H18#H18\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Congenital myotonic dystrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory involvement is the leading cause of death in the neonatal period. Need for support longer than four weeks usually indicates a poor prognosis for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Nasal continuous positive airway pressure (N-CPAP) can facilitate weaning infants with DM1 from endotracheal mechanical ventilation and minimize morbidity associated with prolonged intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because feeding difficulties are common during the first two years of life, children with congenital DM1 are at increased risk for aspiration and may benefit from feeding evaluation. Gastrostomy tube insertion is often necessary during the first six months of life to maintain nutrition and prevent aspiration pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cataracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slit-lamp examination to detect cataracts is appropriate at the time of diagnosis and periodically thereafter, as dictated by symptoms in both DM1 and DM2 patients. In the congenital form of DM1, cataracts are uncommon before the age of 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corrective surgery is indicated if symptoms from the cataract interfere with the patient's activities of daily living, and surgery is needed in a substantial minority of patients. In one series of 164 patients with DM1, cataract surgery was carried out in 21 (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/27\">",
"     27",
"    </a>",
"    ], and in another series of 234 patients with DM2, cataract extraction was performed in 75 (32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and treatment of cataracts is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Myotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of myotonia in patients with DM1 can be sufficiently pronounced to prompt treatment. Myotonic symptoms in DM2 are less likely to require therapy.",
"   </p>",
"   <p>",
"    A systematic review published in 2006 found 10 small randomized controlled trials that evaluated the effectiveness of 12 different treatments for DM1 in patients with myotonic dystrophy and myotonia congenita [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the quality of the trials was generally poor, and a meta-analysis was not possible.",
"   </p>",
"   <p>",
"    The clinical experience of treating myotonia has involved a variety of medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , all of which are sodium channel blockers and share the potential to increase weakness while reducing myotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/21,31\">",
"     21,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two small seven-week double-blind randomized controlled trials involving patients with DM1, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    (at either 450 mg or 600 mg daily, both given in three divided doses) was superior to placebo for improvement in grip relaxation time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/32\">",
"     32",
"    </a>",
"    ]. Mexiletine was well-tolerated in these trials and was not associated with any serious adverse effects or cardiac conduction abnormalities.",
"   </p>",
"   <p>",
"    Because of the rare pro-arrhythmic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    in those with underlying ventricular arrhythmias, it is best to obtain cardiac consultation before beginning therapy with mexiletine, particularly for patients with DM1 who have current or remote cardiac symptoms or for those with an abnormal baseline ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     Mexiletine",
"    </a>",
"    is contraindicated in instances of second and third degree heart block. Ataxia, coordination abnormalities, and dizziness are relatively common side effects, and ongoing hematologic, liver function, and cardiac monitoring must be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For adults with myotonic symptoms that require treatment (typically in DM1), we suggest initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    450 mg daily in three divided doses, once a cardiology evaluation for risk assessment has been obtained.",
"   </p>",
"   <p>",
"    In children and adolescents, in whom myotonia may occasionally need to be treated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    (1.5 to 3.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 to 12 hours) may be used with careful follow-up. Children should also have a cardiology evaluation prior to starting mexiletine because the drug may worsen bradycardias and other arrhythmias. As in adults, mexiletine is contraindicated in patients with second or third degree heart block and requires periodic hematologic and liver function monitoring.",
"   </p>",
"   <p>",
"    Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    have also demonstrated efficacy in relieving myotonia, but their use is not recommended because unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , they exhibit adverse effects on cardiac conduction, to which patients with DM may be especially vulnerable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Excessive daytime sleepiness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2006 systematic review found only three trials that had evaluated the effectiveness of pharmacologic therapy for excessive daytime sleepiness (EDS) in myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       Modafinil",
"      </a>",
"      was evaluated in two trials that included a total of 60 adults with myotonic dystrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Both trials suggested that modafinil was modestly beneficial for the treatment of daytime sleepiness, as assessed by the Epworth sleepiness scale, and was well tolerated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link&amp;anchor=H14#H14\">",
"       \"Quantifying sleepiness\", section on 'Epworth sleepiness scale (ESS)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       Selegiline",
"      </a>",
"      failed to show any benefit for hypersomnolence in one trial of 11 patients with myotonic dystrophy, but major methodologic flaws precluded definitive conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The systematic review identified no trials that evaluated the use of pharmacologic agents for EDS in children with myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the limited evidence from randomized controlled trials, we suggest a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    (200 mg twice daily) for adult patients with myotonic dystrophy and severe EDS.",
"   </p>",
"   <p>",
"    Since obstructive sleep apnea (OSA) may coexist with central hypoventilation, consideration should be given to overnight polysomnography, especially in those at highest risk due to coexisting obesity. The hypersomnia of DM1 may be aggravated by alveolar hypoventilation and the sleep apnea syndrome but is not entirely reversed by continuous positive airway pressure management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk of anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited to observational case series or case reports, most [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/37-42\">",
"     37-42",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/43\">",
"     43",
"    </a>",
"    ] of these studies suggest that patients with myotonic dystrophy are at high risk during general anesthesia.",
"   </p>",
"   <p>",
"    It is known that myotonia may be precipitated by hypothermia, shivering, or mechanical or electrical stimulation. Patients may have cardiac conduction system abnormalities such as supraventricular and ventricular arrhythmias; laryngeal and pharyngeal muscle weakness may predispose to aspiration. Thus, most experts believe that the combination of neuromuscular, cardiac, and respiratory abnormalities places these patients at particular risk for general anesthesia. The higher sensitivity to sedatives and anesthetic and neuromuscular blocking agents may result in cardiovascular and respiratory complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a separate issue, there is limited evidence that myotonic dystrophy may increase the risk of malignant hyperthermia with anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data regarding the risk of anesthesia in DM2. An observational study of patients with DM2 reported that none experienced problems during general anesthesia, but did not state how many patients had such anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we recommend that patients with myotonic dystrophy, particularly those with DM1, avoid general anesthesia when possible.",
"    <span class=\"nowrap\">",
"     Regional/spinal",
"    </span>",
"    anesthesia is a possible alternative for some patients with DM1 and DM2 who require surgery. For patients who must have general anesthesia, preoperative assessments of cardiac and pulmonary function may identify patients at particularly high risk for surgery, and close monitoring for postoperative apnea may reduce the risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When sedation is necessary, we suggest use of a short acting agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , and avoidance of long-acting sedatives such as the benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/44\">",
"     44",
"    </a>",
"    ]. Likewise, short-acting muscle relaxants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    are preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    to minimize muscle activation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/27\">",
"     27",
"    </a>",
"    ]. Opiates should be used sparingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM1 is inherited in an autosomal dominant manner, and therefore the offspring of an individual with a premutation (a phenotypically normal person with a mutable gene of CTG repeat size 35 to 49) or offspring of a phenotypically involved individual (abnormal gene with CTG repeat size of &ge;50) with a frank mutation has a 50 percent chance of inheriting the mutant allele [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/49\">",
"     49",
"    </a>",
"    ]. There is no evidence of preferential transmission of the mutated allele [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease-causing alleles may expand in length during gametogenesis, resulting in the transmission of longer CTG repeat alleles that may be associated with earlier onset and more severe disease phenotype than observed in the parent, the phenomenon of anticipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H2#H2\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Importantly, when the disease is transmitted by a male, the mean intergenerational variation is minimal (56 CTG repeats); however, when the mother is the affected parent, the intergenerational expansion is very high (948 CTG repeats) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, for increasing paternal individual expansion, the fetal expansion tends to remain stable or decrease, while for the mothers, the CTG repeat increases as the maternal expansion increases. Others have also shown that the majority (66 percent) of maternal transmission revealed anticipation, whereas the majority (69 percent) of paternal transmission resulted in contractions or transmission of stable alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of giving birth to a child with congenital myotonic dystrophy is related to intergenerational amplification and is estimated at 60 to 100 percent if the maternal expansion is &gt;900 repeats, and the risk is &lt;12 percent if the expansion is &lt;600 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/51\">",
"     51",
"    </a>",
"    ]. It is important to note, however, that the available data have wide confidence limits, and, therefore, making risk assessment estimates is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal expansion is the underlying basis for the observation that congenital DM infants typically have an affected mother. Although it is common for neonatal cases (those with congenital myotonic dystrophy) to be born from symptomatic mothers with multisystem involvement, it is also not unusual for the mother of a neonate affected with congenital myotonic dystrophy to be asymptomatic, and subsequently be found to have an abnormal CTG expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal testing is available for pregnancies at risk for DM1 by analysis of DNA extracted from fetal cells obtained by amniocentesis at 15 to 18 weeks gestation, or chorionic villus sampling at 10 to 12 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/49\">",
"     49",
"    </a>",
"    ]. It is important that molecular confirmation of the diagnosis (CTG expansion in the DM1 gene locus) be undertaken before prenatal testing is performed, and it is best that molecular diagnosis not only be confirmed in symptomatic parents but also that evidence of mutant alleles be sought in the asymptomatic parent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For testing of symptomatic and at-risk asymptomatic adults, several points are germane with regard to DM1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a general rule, patients having larger CTG expansions in circulating leukocytes have an earlier onset of more severe symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The probability of developing an asymptomatic or mild phenotype is nearly 100 percent for patients with expansions of &le;100 CTG repeats [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, those with 2000 repeats have a &gt;90 percent chance of developing the most severe phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For the patients with DM1 and a repeat size between 100 and 2000, there is great variation. As an example, with 400 repeats, the risk of mild, moderately severe, and severe disease is 19, 72, and 9 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In DM2, testing of at-risk symptomatic adults can determine whether an individual has a CCTG expansion and, thus, whether he or she is at risk to develop the disease. Probands with de novo mutations have not been reported, and all affected individuals whose biological parents have been tested have had one parent with a CCTG repeat expansion. In contrast to DM1, the repeat size cannot predict age of onset, severity, or clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/52\">",
"     52",
"    </a>",
"    ]. Again, in contrast to DM1, there is an absence of a congenital (severe) form of the disease.",
"   </p>",
"   <p>",
"    The other notable difference between DM1 and DM2 is the behavior of the repeat size, which tends to contract when passed to the next generation in DM2 families (and tends to expand in DM1 transmissions), and then increases as the individual ages. There is no maternal or paternal preference for contraction or expansion in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18057/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in DM1, prenatal testing for pregnancies at 50 percent risk for DM2 is possible when the presence of a mutation has been confirmed in an affected parent. However, such testing is not commonly done for a condition like DM2 that typically has an adult-onset and does not have a major impact on the intellect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=see_link\">",
"       \"Patient information: Muscular dystrophy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=see_link\">",
"       \"Patient information: Overview of muscular dystrophies (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no disease-modifying therapy available for the treatment of myotonic dystrophy. Treatment is symptomatic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life expectancy is reduced for patients with the congenital form of DM1 and classic DM1 (weakness, myotonia, extramuscular manifestations) with onset in childhood, adolescence or adult life. Mild DM1, manifested by cataracts, mild myotonia, and typically with &lt;150 CTG repeats in the DMPK gene locus, has an essentially normal life span. Respiratory and cardiac diseases are the most common causes of death in DM1. Definitive information about prognosis is not available for DM2, but it would appear to have a more benign course with relatively little diminution of life span. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of DM1 is that of gradual progression in weakness. Management of physical disability depends on the distribution and severity of muscle weakness and is best provided by a multidisciplinary team. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescent and adult patients with DM1 and adults with DM2 who are able to participate, have a normal ECG, and are free from cardiac symptoms, we suggest low-intensity exercise training as tolerated and without undue physical stress (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with cardiac symptoms or an abnormal baseline ECG, we suggest exercise testing with ECG monitoring prior to beginning an exercise training program, since exercise can trigger arrhythmias. In this group of patients, a decision regarding the safety of exercise training should be made by a cardiologist. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Exercise training'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest periodic respiratory assessment with serial forced vital capacity (FVC) measurement for adult patients with DM1. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Respiratory function and sleep'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonates with congenital DM1 often require continuous ventilatory support and gastrostomy tube feeding. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Congenital myotonic dystrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Swallowing assessment is an important part of the management of patients with DM1. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dysphagia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with DM1 and DM2, we suggest electrocardiograms at least once a year to screen for cardiac conduction disturbances. When arrhythmias are suspected clinically but are not detected on standard ECG, we suggest 24-hour ambulatory ECG monitoring. We suggest echocardiography if symptoms or signs of myocardial dysfunction are present. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac conduction disturbances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For occasional adult patients who have severe myotonia that interferes with function, we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      450 or 600 mg daily in three divided doses (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children with severe myotonia, we suggest oral mexiletine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The suggested pediatric dose of mexiletine is discussed above. Adults and children should have a cardiology evaluation for risk assessment before starting treatment with mexiletine. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Myotonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adult patients with DM1 and severe excessive daytime sleepiness, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      (200 mg twice daily) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Excessive daytime sleepiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with myotonic dystrophy, particularly those with DM1, appear to have an increased risk of complications with general anesthesia. The risk of general anesthesia in patients with DM2 is uncertain. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Risk of anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/1\">",
"      Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/2\">",
"      Mathieu J, Allard P, Potvin L, et al. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999; 52:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/3\">",
"      de Die-Smulders CE, H&ouml;weler CJ, Thijs C, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998; 121 ( Pt 8):1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/4\">",
"      Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008; 358:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/5\">",
"      M&ouml;rner S, Lindqvist P, Mellberg C, et al. Profound cardiac conduction delay predicts mortality in myotonic dystrophy type 1. J Intern Med 2010; 268:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/6\">",
"      Nazarian S, Wagner KR, Caffo BS, Tomaselli GF. Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol 2011; 34:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/7\">",
"      Reardon W, Newcombe R, Fenton I, et al. The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child 1993; 68:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/8\">",
"      Schoser BG, Ricker K, Schneider-Gold C, et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/9\">",
"      Groh WJ, Groh MR, Shen C, et al. Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. Muscle Nerve 2011; 43:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/10\">",
"      Roig M, Balliu PR, Navarro C, et al. Presentation, clinical course, and outcome of the congenital form of myotonic dystrophy. Pediatr Neurol 1994; 11:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/11\">",
"      Gagnon C, Noreau L, Moxley RT, et al. Towards an integrative approach to the management of myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry 2007; 78:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/12\">",
"      Mathieu J, Boivin H, Richards CL. Quantitative motor assessment in myotonic dystrophy. Can J Neurol Sci 2003; 30:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/13\">",
"      Whittaker RG, Ferenczi E, Hilton-Jones D. Myotonic dystrophy: practical issues relating to assessment of strength. J Neurol Neurosurg Psychiatry 2006; 77:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/14\">",
"      Wiles CM, Busse ME, Sampson CM, et al. Falls and stumbles in myotonic dystrophy. J Neurol Neurosurg Psychiatry 2006; 77:393.",
"     </a>",
"    </li>",
"    <li>",
"     Dalton JC, Ranum LPW, Day JW. Myotonic dystrophy type 2. GeneReviews www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=myotonic-d2 (Accessed on January 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/16\">",
"      Lindeman E, Leffers P, Spaans F, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 1995; 76:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/17\">",
"      van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2005; :CD003907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/18\">",
"      Orngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol 2005; 57:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/19\">",
"      Bassez G, Lazarus A, Desguerre I, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004; 63:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/20\">",
"      Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/21\">",
"      Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/22\">",
"      Culebras A. Sleep and neuromuscular disorders. Neurol Clin 2005; 23:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/23\">",
"      Sartoretti C, Sartoretti S, DeLorenzi D, Buchmann P. Intestinal non-rotation and pseudoobstruction in myotonic dystrophy: case report and review of the literature. Int J Colorectal Dis 1996; 11:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/24\">",
"      Sj&ouml;green L, Tulinius M, Kiliaridis S, Lohmander A. The effect of lip strengthening exercises in children and adolescents with myotonic dystrophy type 1. Int J Pediatr Otorhinolaryngol 2010; 74:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/25\">",
"      Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012; 307:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/26\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     Harper PS. Myotonic Dystrophy, 3rd, WB Saunders, London 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/28\">",
"      Moxley RT 3rd. Carrell-Krusen Symposium Invited Lecture-1997. Myotonic disorders in childhood: diagnosis and treatment. J Child Neurol 1997; 12:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/29\">",
"      Keller C, Reynolds A, Lee B, Garcia-Prats J. Congenital myotonic dystrophy requiring prolonged endotracheal and noninvasive assisted ventilation: not a uniformly fatal condition. Pediatrics 1998; 101:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/30\">",
"      Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev 2006; :CD004762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/31\">",
"      Kurihara T. New classification and treatment for myotonic disorders. Intern Med 2005; 44:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/32\">",
"      Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/33\">",
"      Annane D, Moore DH, Barnes PR, Miller RG. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. Cochrane Database Syst Rev 2006; :CD003218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/34\">",
"      MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002; 59:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/35\">",
"      Talbot K, Stradling J, Crosby J, Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord 2003; 13:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/36\">",
"      Antonini G, Morino S, Fiorelli M, et al. Selegiline in the treatment of hypersomnolence in myotonic dystrophy: a pilot study. J Neurol Sci 1997; 147:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/37\">",
"      Mudge BJ, Taylor PB, Vanderspek AF. Perioperative hazards in myotonic dystrophy. Anaesthesia 1980; 35:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/38\">",
"      Aldridge LM. Anaesthetic problems in myotonic dystrophy. A case report and review of the Aberdeen experience comprising 48 general anaesthetics in a further 16 patients. Br J Anaesth 1985; 57:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/39\">",
"      Moore JK, Moore AP. Postoperative complications of dystrophia myotonica. Anaesthesia 1987; 42:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/40\">",
"      Anderson BJ, Brown TC. Congenital myotonic dystrophy in children--a review of ten years' experience. Anaesth Intensive Care 1989; 17:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/41\">",
"      Mathieu J, Allard P, Gobeil G, et al. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 1997; 49:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/42\">",
"      Rosenbaum HK, Miller JD. Malignant hyperthermia and myotonic disorders. Anesthesiol Clin North America 2002; 20:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/43\">",
"      Imison AR. Anaesthesia and myotonia--an Australian experience. Anaesth Intensive Care 2001; 29:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/44\">",
"      Klompe L, Lanc&eacute; M, van der Woerd D, et al. Anaesthesiological and ventilatory precautions during cardiac surgery in Steinert's disease. J Card Surg 2007; 22:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/45\">",
"      Aquilina A, Groves J. A combined technique utilising regional anaesthesia and target-controlled sedation in a patient with myotonic dystrophy. Anaesthesia 2002; 57:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/46\">",
"      SAIDMAN LJ, HAVARD ES, EGER EI 2nd. HYPERTHERMIA DURING ANESTHESIA. JAMA 1964; 190:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/47\">",
"      Moulds RF, Denborough MA. Letter: Myopathies and malignant hyperpyrexia. Br Med J 1974; 3:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/48\">",
"      Lehmann-Horn F, Iaizzo PA. Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? Br J Anaesth 1990; 65:692.",
"     </a>",
"    </li>",
"    <li>",
"     Bird TD. Myotonic dystrophy type 1. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=myotonic-d#myotonic-d (Accessed on January 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/50\">",
"      Martorell L, Cobo AM, Baiget M, et al. Prenatal diagnosis in myotonic dystrophy type 1. Thirteen years of experience: implications for reproductive counselling in DM1 families. Prenat Diagn 2007; 27:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18057/abstract/51\">",
"      Salehi LB, Bonifazi E, Stasio ED, et al. Risk prediction for clinical phenotype in myotonic dystrophy type 1: data from 2,650 patients. Genet Test 2007; 11:84.",
"     </a>",
"    </li>",
"    <li>",
"     Dalton JC, Ranum LPW, Day JW. Myotonic dystrophy type 2. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=myotonic-d2 (Accessed on January 21, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5140 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18057=[""].join("\n");
var outline_f17_40_18057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DM2 prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muscle pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exercise training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk of statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RESPIRATORY FUNCTION AND SLEEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DYSPHAGIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARDIAC CONDUCTION DISTURBANCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Congenital myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cataracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Myotonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Excessive daytime sleepiness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk of anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=related_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=related_link\">",
"      Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_40_18058="Hyperkinetic movement disorders in children";
var content_f17_40_18058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperkinetic movement disorders in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18058/contributors\">",
"     Joseph Jankovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18058/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18058/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18058/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/40/18058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/40/18058/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/40/18058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Movement disorders are characterized by either excessive (hyperkinetic) or reduced (bradykinetic) activity. Hyperkinetic disorders are reviewed here. Bradykinetic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link\">",
"     \"Bradykinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperkinetic disorders are characterized by abnormal involuntary movement. These excess movements can be regular and rhythmic, as in tremor; more sustained and patterned, as in dystonia; brief and random, as in chorea; or jerk-like and temporarily suppressible, as in tics. Diagnosis of the specific condition depends primarily upon careful observation of the clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/1\">",
"     1",
"    </a>",
"    ]. Tics are the most common hyperkinetic disorder in children. Dystonia, stereotypies, choreoathetosis, tremors, and myoclonus also occur but are less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE BASAL GANGLIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief review of the anatomy of the basal ganglia is appropriate since this site is involved in many of the bradykinetic disorders. The basal ganglia regulate the initiation, scaling, and control of the amplitude and direction of movement. Movement disorders can result from biochemical or structural abnormalities in these structures.",
"   </p>",
"   <p>",
"    The basal ganglia are a complex of deep nuclei that consist of the corpus striatum, globus pallidus, and substantia nigra. The corpus striatum, which includes the caudate nucleus and the putamen, receives input from the cerebral cortex and the thalamus and, in turn, projects to the globus pallidus.",
"   </p>",
"   <p>",
"    The substantia nigra is divided into the dopamine-rich pars compacta and the less dense pars reticularis. The pars reticularis is similar histologically and chemically to the medial segment of the globus pallidus, and both project via the thalamus to the premotor and motor cortex. The substantia nigra pars compacta gives rise to the nigral-striatal pathway, which is the main dopaminergic tract.",
"   </p>",
"   <p>",
"    The output of the basal ganglia projects by way of the thalamus to the cerebral cortex and then to the pyramidal system. Basal ganglia output is sometimes referred to as the extrapyramidal system because it was formerly thought to be in parallel with the pyramidal system. Integration of the basal ganglia with the cortex facilitates motor control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by the Taskforce on Childhood Movement Disorders, &ldquo;tics are repeated, individually recognizable, intermittent movements or movement fragments that are almost always briefly suppressible and are usually associated with awareness of an urge to perform the movement&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"     2",
"    </a>",
"    ]. Tics manifest as sudden, brief intermittent movements (motor tics) or utterances (vocal or phonic tics). Unlike dyskinetic movements and dystonias, tics cease during sleep. Although tics can be voluntarily controlled for short periods of time, it is difficult to suppress tics for sustained periods of time. Transient tic disorders are particularly common during childhood, when they occur in up to 25 percent of normal children. Most children with simple motor tics do not require treatment.",
"   </p>",
"   <p>",
"    Persistent motor and phonic tics are features of Tourette syndrome, as described below (",
"    <a class=\"graphic graphic_table graphicRef61505 \" href=\"UTD.htm?20/1/20508\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Secondary causes should be considered in individuals in whom tics begin abruptly, are persistent, or are particularly problematic. Secondary causes of tics include the use of stimulant medications (dopaminergic agonists). Another potential but controversial cause is pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of streptococcal tonsillopharyngitis\", section on 'PANDAS syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tourette syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tourette syndrome (TS) is reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link\">",
"     \"Tourette syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tourette syndrome is a common movement and neurobehavioral disorder in children. The hallmark of TS is the occurrence of multiple motor and vocal (phonic) tics. Tics in TS may be simple, involving a single muscle or muscle group, or complex, involving sequential, coordinated movements. Simple tics include blinking, facial grimacing, shoulder shrugging, and head jerking. Complex tics include bizarre gait, kicking, jumping, body gyrations, and seductive or obscene gestures. Involuntary vocalizations may include simple noises to more complex utterances such as coprolalia (shouting of obscenities or profanities), echolalia (repeating what others say), and palilalia (repeating the patient's own words or phrases).",
"   </p>",
"   <p>",
"    TS must be differentiated from transient tics, which occur in otherwise normal children and spontaneously remit in a few weeks or months (",
"    <a class=\"graphic graphic_table graphicRef61505 \" href=\"UTD.htm?20/1/20508\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DYSTONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by the Taskforce on Childhood Movement Disorders, &ldquo;dystonia is a movement disorder in which involuntary sustained or intermittent muscle contractions cause twisting and repetitive movements, abnormal postures, or both&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"     2",
"    </a>",
"    ]. Dystonic movements may be either slow or rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/3\">",
"     3",
"    </a>",
"    ]. Dystonic states are classified as primary, secondary, or psychogenic depending upon the cause (",
"    <a class=\"graphic graphic_table graphicRef70477 graphicRef51622 graphicRef63377 \" href=\"UTD.htm?1/4/1103\">",
"     table 2A-C",
"    </a>",
"    ). By definition, primary dystonia (formerly known as dystonia musculorum deformans or idiopathic torsion dystonia) is associated with no other neurologic impairment, such as intellectual, pyramidal, cerebellar, or sensory deficits. However, tremor that appears identical to essential tremor occurs in approximately 20 percent of patients with this condition. In some families, dystonia and essential tremor coexist. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Essential tremor'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cerebral palsy probably is the most common cause of secondary dystonia seen in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of involuntary movements occurs before age 20 in approximately 30 percent of patients with dystonia. The distribution of the affected muscle groups appears to depend upon age. The disorder typically begins distally in children, whereas a cranial-cervical distribution is more common in adults. Childhood dystonia usually progresses to a generalized disorder, whereas adult dystonia usually remains focal or segmental [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of severity of dystonia is variable and may depend upon the situation. As an example, some patients have task-specific dystonias that occur only when they participate in certain activities, such as writing, typing, or playing the piano (\"musician's hands\") [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/5\">",
"     5",
"    </a>",
"    ]. As the dystonia worsens, it typically extends to adjacent muscles and eventually occurs even at rest. In rare cases, the spasms become severe and may cause cervical disc, nerve, or root problems [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/6\">",
"     6",
"    </a>",
"    ]. Muscle breakdown with myoglobinuria (\"dystonic storm\") also can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No specific morphologic changes have been noted in neuropathologic examinations of patients with primary dystonia. In the brains of a few patients, the norepinephrine concentration was markedly reduced in the posterior and lateral hypothalamus and increased in the red nucleus, suggesting a neurotransmitter abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/8\">",
"     8",
"    </a>",
"    ]. However, further studies are needed to confirm these findings. The fluorodopa positron emission tomography (PET) scan is usually normal, although (18F) fluorodeoxyglucose shows an abnormal pattern of metabolic activity when data are averaged from a large group of dystonic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dystonia may be sporadic or inherited. Cases with onset in childhood usually are inherited in an autosomal dominant pattern (",
"    <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"     table 3",
"    </a>",
"    ). Many hereditary cases are caused by a defect in torsinA, a protein with uncertain function that is expressed in the brain. A rare cause of hereditary dystonia is dopa-responsive dystonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     DYT1 dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with hereditary dystonia have a mutation in the TOR1A (DYT1) gene that encodes the protein torsinA, an ATP-binding protein in the 9q34 locus. DYT1 dystonia is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link&amp;anchor=H17#H17\">",
"     \"Classification and evaluation of dystonia\", section on 'DYT1 dystonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dopa-responsive dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopa-responsive dystonia (DRD) is an unusual form of hereditary progressive dystonia that begins during the first decade after birth. The dystonia usually starts in the legs and becomes generalized. Some patients may also have hyperreflexia, rigidity, tremor, and other parkinsonian features, and less commonly, cerebellar signs. The most frequent form of DRD is autosomal dominant DYT5 dystonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link&amp;anchor=H19#H19\">",
"     \"Classification and evaluation of dystonia\", section on 'Dopa-responsive dystonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hallmark of DRD is a clinically significant, sustained response to levodopa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link\">",
"     \"Treatment of dystonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Paroxysmal dyskinesia with dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several rare genetic forms of dystonia are characterized by paroxysmal dyskinesia and discussed here briefly (",
"    <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"     table 3",
"    </a>",
"    ). They are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link&amp;anchor=H22#H22\">",
"     \"Classification and evaluation of dystonia\", section on 'Paroxysmal dyskinesia with dystonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal nonkinesigenic dyskinesia (PNKD) is characterized by spontaneous episodes of dystonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      choreoathetosis not triggered by exercise or activity. Alcohol, coffee, tea, fatigue, stress, or excitement may be precipitating factors. Episodes last minutes to hours and recur two or three times a month.",
"     </li>",
"     <li>",
"      Paroxysmal choreoathetosis with episodic spasticity and ataxia (DYT9) manifests with episodes of dystonia, diplopia, and paresthesia. Exercise, emotional stress, sleep deprivation, and alcohol consumption may be precipitating factors. Some patients have a spastic paraparesis.",
"     </li>",
"     <li>",
"      Paroxysmal kinesigenic choreoathetosis, also known as paroxysmal kinesigenic dyskinesia, is characterized by episodic choreoathetosis and dystonia brought on by voluntary movement. The disorder is genetically heterogeneous.",
"     </li>",
"     <li>",
"      Paroxysmal exertion-induced dyskinesia is an autosomal dominant disorder with reduced penetrance that begins in childhood with dyskinesia and dystonia induced by prolonged exertion (eg, &ge;15 minutes), fasting and stress. Associated features include absence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      partial complex seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hemidystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemidystonia (also known as unilateral dystonia) involves one-half of the body and occurs frequently in children and young adults. Approximately 75 percent of patients with hemidystonia have a structural lesion in the contralateral basal ganglia, often the putamen, that resulted from an insult to the brain. Causes associated with these lesions are infarction or hemorrhage (30 percent) and perinatal trauma (20 percent). Hemidystonia often presented several years after the precipitating factor; this delay occurred more often in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute dystonic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute dystonic reaction, usually transient, is a recognized complication of the dopamine receptor-blocking drugs, such as the antipsychotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ) and antiemetics (eg, phenothiazines,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Dystonic reactions also can occur with levodopa, anticonvulsants, antidepressants (eg, selective serotonin reuptake inhibitors), and ergots.",
"   </p>",
"   <p>",
"    Treatment of acute dystonia with antihistamine or anticholinergic medications is usually rapidly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Parenteral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, maximum dose 50 mg) is used most frequently and typically results in resolution of an acute dystonic reaction within minutes. Intravenous administration is preferred over oral administration for initiation of treatment because patients may have difficulty swallowing. Parenteral administration is required for life-threatening dystonia with associated laryngospasm or stridor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/13\">",
"     13",
"    </a>",
"    ]. Diphenhydramine may also be given intramuscularly but the onset of action is delayed compared with intravenous administration. Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    is also effective in the treatment of acute dystonic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the acute dystonic reaction is treated,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    is given orally (1.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) every six hours for one to two days to prevent recurrence. In some cases, however, a single dose of oral diphenhydramine or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18244?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    suffices. The offending drug should be discontinued.",
"   </p>",
"   <p>",
"    Patients treated with dopamine receptor-blocking agents occasionally develop persistent tardive dystonia after the offending drug is stopped. If no spontaneous improvement occurs, they may respond to trials of muscle relaxants, anticholinergic drugs, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192849077\">",
"    <span class=\"h2\">",
"     Neurodegeneration with brain iron accumulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurodegeneration with brain iron accumulation (NBIA) represents a group of disorders that includes pantothenate kinase-associated neurodegeneration, infantile neuroaxonal dystrophy, fatty acid hydroxylase-associated neurodegeneration, aceruloplasminemia, neuroferritinopathy, and possibly other conditions. Although dystonia is often a prominent feature, other hyperkinetic and bradykinetic movement disorders and neurologic deficits may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional causes of paroxysmal or fluctuating dystonia in children include gastroesophageal reflux (Sandifer syndrome), multiple sclerosis, thyrotoxicosis, metabolic disorders (eg, Hartnup disease), paroxysmal dystonia in sleep (hypnogenic dystonia), \"infectious torticollis\", and the GLUT1 deficiency syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/17\">",
"     17",
"    </a>",
"    ]. Dystonia may be erroneously attributed to a postural deformity that results from common musculoskeletal or orthopedic problems such as congenital torticollis or scoliosis. The number of cases of these disorders that actually represent dystonia is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link\">",
"     \"Acquired torticollis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate treatment of dystonia depends upon an accurate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with atypical features, such as impaired intellect, seizures, neuro-ophthalmologic abnormalities, ataxia, corticospinal tract signs, sensory deficits, severe speech disturbance, and unilateral distribution of the dystonia, are more likely to have an underlying disorder that can be treated, such as Wilson disease.",
"   </p>",
"   <p>",
"    The treatment of dystonia is reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link\">",
"     \"Treatment of dystonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For pediatric patients with focal or generalized dystonia of unknown etiology, we recommend a trial of levodopa to confirm or exclude the diagnosis of dopa-responsive dystonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of dystonia\", section on 'Choosing therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with multifocal or generalized primary dystonia who do not respond to levodopa can be treated with other oral medications, botulinum toxin injections, or deep brain stimulation in refractory cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children with debilitating generalized primary dystonia that does not respond to a trial of levodopa, treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18244?source=see_link\">",
"       trihexyphenidyl",
"      </a>",
"      is suggested. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of dystonia\", section on 'Drug treatments'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For debilitating multifocal or generalized primary dystonia that does not respond to pharmacologic treatment, we suggest botulinum toxin injection of selected muscles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of dystonia\", section on 'Botulinum toxin injections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with debilitating multifocal or generalized primary dystonia who do not respond to pharmacologic therapy or botulinum toxin injections, we suggest bilateral deep brain stimulation of the internal globus pallidus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of dystonia\", section on 'Deep brain stimulation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STEREOTYPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by the Taskforce on Childhood Movement Disorders, &ldquo;stereotypies are repetitive, simple movements that can be voluntarily suppressed&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"     2",
"    </a>",
"    ]. Examples include repetitive chewing, rocking, twirling, or touching. These movements typically occur in children with infantile autism or mental retardation (",
"    <a class=\"graphic graphic_table graphicRef78875 \" href=\"UTD.htm?27/26/28075\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Motor mannerisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, stereotypies also can occur in otherwise normal children. The clinical features and course of complex stereotypies of the upper extremity were described in a case series of 40 children and adolescents from a tertiary specialty clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/19\">",
"     19",
"    </a>",
"    ]. The following features were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age was 7.9 years",
"     </li>",
"     <li>",
"      90 percent had onset before 3 years of age",
"     </li>",
"     <li>",
"      90 percent had occurrence at least daily, but were not reported to occur during sleep",
"     </li>",
"     <li>",
"      The typical duration of episodes ranged from &lt;10 seconds (30 percent) to &gt;60 seconds (30 percent)",
"     </li>",
"     <li>",
"      The movement involved flapping in 48 percent, shaking in 28 percent, clenching-stiffening-posturing in 38 percent, and ritual in 13 percent of patients",
"     </li>",
"     <li>",
"      The movement stopped when cued in all but one patient",
"     </li>",
"     <li>",
"      Triggers included excitement, boredom, being focused or engrossed, and",
"      <span class=\"nowrap\">",
"       anxiety/stress",
"      </span>",
"     </li>",
"     <li>",
"      25 percent had comorbid attention deficit hyperactivity disorder",
"     </li>",
"     <li>",
"      20 percent had comorbid learning disability",
"     </li>",
"     <li>",
"      25 percent had a positive family history of stereotypies",
"     </li>",
"     <li>",
"      The clinical course involved resolution in 5 percent, improvement in 33 percent, no change in 50 percent, and worsening in 13 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Rett syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rett syndrome is an example of a disorder characterized by marked stereotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/20\">",
"     20",
"    </a>",
"    ]. This condition is one of the most common causes of mental retardation in females. Most cases are caused by mutations in the gene for methyl-CpG-binding protein 2 (MeCP2).",
"   </p>",
"   <p>",
"    Rett syndrome typically presents at six to 18 months of age in girls with previously normal growth and development. Affected patients regress in their verbal and motor skills, lose purposeful use of their hands, and have jerky ataxia and typical stereotyped movements of the hands resembling hand washing and kneading. Other symptoms include breath-holding spells, hyperventilation, loss of facial expression, poor eye contact, bruxism, dystonia, occasional seizures, apparent insensitivity to pain, and a variety of self-injurious and aggressive behaviors.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis and management of Rett syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link\">",
"     \"Rett syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CHOREA, ATHETOSIS, AND BALLISMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children can be affected by many acquired and hereditary types of chorea and related movement disorders (",
"    <a class=\"graphic graphic_table graphicRef79166 \" href=\"UTD.htm?8/12/8397\">",
"     table 5",
"    </a>",
"    ). The following definitions from the Taskforce on Childhood Movement Disorders apply [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chorea is an ongoing random-appearing sequence of one or more discrete involuntary movements or movement fragments.",
"     </li>",
"     <li>",
"      Athetosis is defined as &ldquo;a slow, continuous, involuntary writhing movement that prevents maintenance of a stable posture&rdquo; and thus represents a form of slow chorea; ballism (ballismus) is defined &ldquo;as chorea that affects proximal joints such as shoulder or hip&rdquo;, leading to &ldquo;large amplitude movements of the limbs, sometimes with a flinging or flailing quality&rdquo;; it is usually unilateral (hemiballismus) and often results from a lesion in the contralateral subthalamic nucleus and adjacent structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physiologic chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all normal infants make movements that resemble chorea, but this physiologic chorea resolves by eight months of age. Children with attention deficit disorder and hyperactivity may have distal chorea (chorea minima).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cerebral palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy is a common cause of chorea in children. Chorea or athetosis (choreoathetosis) is the predominant motor disturbance in approximately one-third of cases but occurs to a variable degree in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/21\">",
"     21",
"    </a>",
"    ]. In one series, choreoathetosis was apparent in one-half of patients during the first year and developed in the remainder during the next four to five years, after which it remained static. Most patients with athetoid cerebral palsy were born prematurely (60 percent) or had a perinatal history of jaundice",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asphyxia (82 percent). Dystonia also is common, occurring in up to 70 percent of cases.",
"   </p>",
"   <p>",
"    Several patients have been reported with choreoathetosis and dystonia that is delayed in onset and progressive, in contrast to the nonprogressive neurologic impairment in cerebral palsy. The mechanism is attributed to sprouting and denervation supersensitivity of receptors in the basal ganglia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Sydenham chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sydenham chorea (SC) is one of the major clinical manifestations of acute rheumatic fever and the most common form of acquired chorea in childhood. The initial presentation typically occurs in patients between 5 and 13 years of age. This disorder is discussed in detail elsewhere and will be reviewed briefly here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=see_link\">",
"     \"Sydenham chorea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chorea usually develops one to eight months after the inciting infection, in contrast to carditis and arthritis which most often present within 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/22\">",
"     22",
"    </a>",
"    ]. The onset is usually insidious but may be abrupt.",
"   </p>",
"   <p>",
"    The chorea typically begins with distal movements of the hands, but generalized jerking of the face and feet emerges as the chorea becomes more active. The movements are rapid, irregular, and nonstereotyped jerks that are continuous while the patient is awake but improve with sleep. The chorea is usually generalized but may be more prominent on one side; approximately 20 percent of patients have hemichorea (ie, unilateral chorea). Emotional changes, such as easy crying or inappropriate laughing, may precede the development of chorea. In some cases, regression in school performance is the initial concern.",
"   </p>",
"   <p>",
"    The diagnosis of SC is made clinically as no specific laboratory test exists. Although the neuropathology of SC is not well studied, vasculitis involving the basal ganglia, cortex, and cerebellum has been identified in the brains of some affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sydenham chorea typically improves gradually, with a mean duration of 12 to 15 weeks. Treatment includes antibiotic therapy with penicillin for at least 10 days followed by antibiotic prophylaxis. Specific treatment for the chorea may be warranted when significant impairment of motor function and the possibility of self-injury are present. Treatments reported to be effective include valproic acid,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=see_link\">",
"     pimozide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . Corticosteroids may shorten the course of SC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=see_link&amp;anchor=H8#H8\">",
"     \"Sydenham chorea\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Post pump chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dyskinetic movement disorder may complicate cardiac surgery in a small number of children with congenital heart disease. The estimated frequency of this complication is 10 percent (0.6 to 18 percent) per procedure, but the incidence appears to be decreasing over time, presumably as a result of changing operative techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complication has been described in children ages six weeks to 52 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. Risk factors include more time on pump, deeper hypothermia (&lt;36 degrees), and circulatory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms begin three to twelve days postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. The dyskinesia is usually in the form of choreoathetosis and mainly involves the mouth, tongue and face [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/28\">",
"     28",
"    </a>",
"    ]. More severely affected children have involvement of extremities and trunk. Neuroimaging studies and EEG are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying etiology is not understood. In two patients, neuropathologic findings included neuronal loss, reactive astrocytosis, and degeneration of myelinated fibers in the globus pallidus, primarily the outer segment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/29\">",
"     29",
"    </a>",
"    ]. Locations typically affected by hypoxic ischemic insult were spared. In some milder and transient cases, certain medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"     captopril",
"    </a>",
"    ) have been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The movements remit in some children over several weeks; others, particularly those who are more severely affected, have persistent chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24\">",
"     24",
"    </a>",
"    ]. Associated neurological deficits are common and range from mild learning deficits to hypotonia and obtundation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24\">",
"     24",
"    </a>",
"    ]. Severely affected children may die. In one series, 1 of 8 died [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24\">",
"     24",
"    </a>",
"    ]; in another, 3 of 36 died [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/27\">",
"     27",
"    </a>",
"    ]. Abnormal motor, cognitive and behavioral development is the rule among children followed over several years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. Older children and those most severely affected at onset appear to be a higher risk for serious and more persistent deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other acquired causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kernicterus is a neurologic condition that may occur when serum total bilirubin concentrations in the perinatal period are excessive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/33\">",
"     33",
"    </a>",
"    ]. In the chronic phase, the disorder is characterized by choreoathetosis, tremor, dystonia, rigidity, dysarthria, sensorineural hearing loss, and limitation of upward gaze. Affected infants may have increased signal intensity in the basal ganglia in T2-weighted magnetic resonance images because of deposition of bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Kernicterus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some infants with severe bronchopulmonary dysplasia develop a movement disorder similar to chorea. In one report describing 10 infants, the condition developed at approximately the third postnatal month and involved the limbs, neck, trunk, and oral-buccal-lingual structures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/35\">",
"     35",
"    </a>",
"    ]. The abnormalities completely or partially resolved in the seven surviving infants. A neuropathologic study of one infant showed neuronal loss with astrocytosis in the caudate, putamen, globus pallidus, and thalamus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hereditary chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntington disease is the most frequent cause of hereditary chorea in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link&amp;anchor=H5#H5\">",
"     \"Bradykinetic movement disorders in children\", section on 'Huntington disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes include benign hereditary chorea and Lesch-Nyhan syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Benign hereditary chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign hereditary chorea (BHC) is an autosomal dominant disorder that presents during infancy or childhood. Nearly all reported patients are heterozygous for mutations in the NKX2-1 gene (also known as the TITF1 gene) on chromosome 14q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As observed in one of the largest reports, which analyzed 28 patients and reviewed the literature, the typical features of BHC include onset in infancy with marked hypotonia followed by generalized chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/38\">",
"     38",
"    </a>",
"    ]. Most children are delayed in motor and walking milestones. Associated neurologic features of BHC may include myoclonus, upper limb dystonia, and motor and vocal tics. The chorea is nonprogressive and often lessens over time or resolves by early adulthood. However, patients who have myoclonus and chorea early in the course of the disease sometimes develop worsening myoclonus, which becomes the major source of disability as the chorea improves [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/39\">",
"     39",
"    </a>",
"    ]. Cognitive and behavioral disturbances, most often learning difficulties, and less often attention deficit hyperactivity disorder or mental retardation, are frequently associated with BHC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequent systemic manifestations of BHC are thyroid disease, with hypothyroidism or thyroid gland abnormalities on ultrasound, and pulmonary disease, manifesting as neonatal respiratory distress or recurrent pulmonary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, the phenotype of BHC includes the syndrome of choreoathetosis, hypothyroidism, and neonatal respiratory distress (also known as brain-thyroid-lung syndrome), which is also caused by mutations in the NKX2-1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic manifestations of BHC may be related to impaired cerebral glucose metabolism in the caudate nucleus, as demonstrated by positron emission tomography with 18F-2-fluorodeoxyglucose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/42\">",
"     42",
"    </a>",
"    ]. However, this finding has not been observed in all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients thought to have BHC require thorough investigation and follow-up because some are diagnosed subsequently with other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/44\">",
"     44",
"    </a>",
"    ]. The main consideration in the differential diagnosis of BHC is myoclonus-dystonia (DYT11) caused by mutations of the SGCE gene [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H15#H15\">",
"     \"Classification and evaluation of myoclonus\", section on 'Myoclonus-dystonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is no established therapy for BHC, one study reported that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for children and 37.5 mg per day for adults) was associated with rapid and lasting improvement in chorea for five of eight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/38\">",
"     38",
"    </a>",
"    ]. In another report, treatment with levodopa (7 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was associated with sustained improvement of gait and chorea for two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Lesch-Nyhan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesch-Nyhan syndrome is a complex motor-behavioral condition that is inherited as an X-linked recessive trait. The disorder results from mutations in the gene coding for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT), leading to deficient enzyme activity. This defect results in an often marked increase in production of uric acid and hyperuricemia.",
"   </p>",
"   <p>",
"    More than 2000 mutations of the HPRT gene have been reported, and the wide spectrum of neurologic symptoms (with some patients being asymptomatic) and severity of the disease have been associated with the degree of enzyme deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected boys have delayed developmental milestones, mental retardation, and extrapyramidal and pyramidal motor symptoms; they also develop self-mutilating behavior.",
"   </p>",
"   <p>",
"    While earlier literature emphasized choreoathetosis and spasticity as typical features of the motor disorder associated with Lesch-Nyhan syndrome, dystonia may be more common. This observation comes from a prospective observational study of a series of 44 patients with complete HPRT deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/50\">",
"     50",
"    </a>",
"    ]. The study found a characteristic evolution of motor involvement, which began at three to six months of age with hypotonia, with or without delayed acquisition of motor skills. Involuntary movements, predominantly dystonia, developed between six and 24 months. Thereafter, the clinical course is relatively static and characterized by severe action dystonia with baseline hypotonia. Extrapyramidal symptoms such as choreoathetosis or ballismus may occur, but are less prominent than dystonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ESSENTIAL TREMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by the Taskforce on Childhood Movement Disorders, &ldquo;tremor is a rhythmic back-and-forth or oscillating involuntary movement about a joint axis&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"     2",
"    </a>",
"    ]. Back-and-forth is further stipulated to mean &ldquo;a relatively symmetric velocity in both directions about a midpoint of the movement, and the velocity or oscillation may appear sinusoidal&rdquo;. Although of relatively constant frequency, the amplitude may be variable. Tremor is caused by either alternating or synchronous contractions of antagonistic muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By definition, tremor should be the only neurologic manifestation of essential tremor (ET). ET usually is a benign condition. However, it may progress to a disabling movement disorder that interferes with feeding, speaking, writing, and other activities of daily living.",
"   </p>",
"   <p>",
"    The cause of ET is uncertain. One form is inherited in an autosomal dominant manner. At least two loci have been identified: one on chromosome 3q13 and one on chromosome 2p22 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Although no neurotransmitter abnormalities have been demonstrated in ET, physiologic studies have demonstrated dysfunction of the cerebellar system.",
"   </p>",
"   <p>",
"    ET is the most common cause of an oscillatory involuntary movement disorder in childhood (",
"    <a class=\"graphic graphic_table graphicRef69074 \" href=\"UTD.htm?3/3/3133\">",
"     table 6",
"    </a>",
"    ). ET may start at any age, including infancy. The clinical features of childhood-onset ET were described in a case series of 39 patients who were evaluated in a movement disorders clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The mean age of onset was 8.8 years (range 1 to 16 years), with a mean age of evaluation of 20.3 years",
"     </li>",
"     <li>",
"      The majority of patients were boys (74 percent)",
"     </li>",
"     <li>",
"      46 percent of patients had some neurologic comorbidity, including dystonia, which was present in 28 percent",
"     </li>",
"     <li>",
"      80 percent of patients reported at least one relative with tremor",
"     </li>",
"     <li>",
"      Exacerbating factors included stress, anxiety, physical activity, and caffeine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two forms of hereditary ET that may begin in infancy are hereditary chin tremor and shuddering attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hereditary chin tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary chin tremor (also called hereditary geniospasm) consists of rhythmic contractions of the chin that occur at a frequency of",
"    <span class=\"nowrap\">",
"     3/sec.",
"    </span>",
"    This condition is inherited in an autosomal dominant pattern, with one locus on chromosome 9q13, and often is associated with deafness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Shuddering attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shuddering attacks begin during infancy or early childhood. Affected children have bursts of rapid trembling of the entire body, occasionally associated with head turning, involuntary sniffing, and throat clearing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. They usually fall to the floor if they have been standing. Attacks may occur during sleep. More than 100 attacks per day may occur; on the other hand, patients may be free of symptoms for as long as two weeks. The episodes tend to decrease in frequency or disappear over time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another form of ET seen in children is an action-postural tremor that consists of slower and faster components. The slower tremor (approximately 6.5 Hz) typically involves the head and neck, whereas the more rapid tremor (8 to 12 Hz) usually involves the hands.",
"   </p>",
"   <p>",
"    Other oscillatory involuntary movements occasionally are seen in infants and children. They include \"head nodding,\" which is often associated with congenital nystagmus, including spasmus mutans, and the \"bobble-headed doll syndrome,\" which occurs with diencephalic lesions, including third-ventricle cysts or tumors, craniopharyngioma, hydrocephalus, and hypothalamic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for ET is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19737?source=see_link\">",
"     \"Pharmacologic treatment of essential tremor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=see_link\">",
"     \"Surgical treatment of essential tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MYOCLONUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by the Taskforce on Childhood Movement Disorders, &ldquo;Myoclonus is a sequence of repeated, often nonrhythmic, brief shock-like jerks due to sudden involuntary contraction or relaxation of one or more muscles&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"     2",
"    </a>",
"    ]. Myoclonus is not coordinated or suppressible and is often activated by volitional movement. Myoclonus can be physiologic or pathologic and can occur as an isolated disorder or associated with seizures or other conditions (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Benign neonatal sleep myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neonatal sleep myoclonus occurs in the first month after birth. It usually occurs in the early stages of sleep and is stimulus-sensitive. It should be differentiated from neonatal seizures and infantile spasms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"     \"Clinical features and diagnosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Essential myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential myoclonus has no associated neurologic deficit, although it may be associated with ET. The disorder is inherited in an autosomal dominant pattern or may occur sporadically. It typically begins before the patient reaches age 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cortical myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical myoclonus consists of continuous, repetitive, focal jerking that sometimes is associated with characteristic electroencephalographic (EEG) changes. The myoclonus may be triggered by external stimuli or evoked by muscle stretch reflex.",
"   </p>",
"   <p>",
"    The underlying mechanism of cortical myoclonus is thought to be a hyperexcitable sensorimotor cortex. In cortical reflex myoclonus, quick, passive movement of a distal phalanx elicits the myoclonic movement. This movement is preceded by a specific EEG event and enhanced amplitude of the somatosensory evoked potential. In cortical action myoclonus, myoclonus is elicited by active movement which may have an EEG correlate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Epilepsia partialis continua",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsia partialis continua (partial status epilepticus) may be associated with myoclonus. Common causes include cortical stroke and Rasmussen encephalitis, which results from a focal cortical lesion or inflammation possibly induced by viral infection.",
"   </p>",
"   <p>",
"    Reticular reflex myoclonus is thought to result from a hyperexcitable brainstem reticular formation, particularly the nucleus reticularis gigantocellularis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Unverricht-Lundborg disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unverricht-Lundborg disease (ULD; MIM #254800), also known as \"Mediterranean\" or \"Baltic\" myoclonus, is one form of progressive myoclonus epilepsy (PME), a condition that consists of myoclonus, seizures, and a progressive clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the EPM1 form, stimulus-sensitive myoclonus usually begins between ages 6 and 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/59\">",
"     59",
"    </a>",
"    ]. Affected patients develop dysarthria, ataxia, intention tremor, and mild intellectual decline; many become bedridden within five years after onset of symptoms. Epileptiform EEG findings may precede symptoms by up to three years. The diagnosis of EPM1 can be confirmed by genetic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    is often effective for EPM1, reducing myoclonus and seizure-frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    has been associated with exacerbations. A French case series suggests that, with improved treatment, the course is not necessarily dire and stabilizes after five to ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/60\">",
"     60",
"    </a>",
"    ]. Among 20 patients with ULD who were followed over 25 years, only three were severely handicapped, and six led fully independent lives. Comprehensive rehabilitative management is also helpful and can extend life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EPM1 is inherited in an autosomal recessive pattern. The responsible cystatin B gene (CSTB) is localized to 21q22 and encodes cystatin B, a cysteine protease inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. Several different mutations have been identified in the CSTB gene in patients with EPM1, but the most common is an unstable expansion of a dodecamer minisatellite repeat unit in the promoter region [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel form of ULD that maps to chromosome 12 has been described in an Arab family [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/65\">",
"     65",
"    </a>",
"    ]. The locus on chromosome 12 (designated EPM1B) does not have genes known to be related to cystatin B or other forms of PME. The clinical phenotype of EPM1B is similar to EPM1, but appears to be distinguished by an earlier age of onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Lafora body disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lafora body disease (MIM #254780) is another form of progressive myoclonus epilepsy (PME) that is characterized by progressive and intractable myoclonic and photoconvulsive seizures, dementia, apraxia, and cortical blindness. Age of onset is usually between ages 11 and 18 years. Total disability typically occurs within five to eight years. Biopsy of the skin (especially in the axillary region) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/66\">",
"     66",
"    </a>",
"    ], liver, muscle, or brain reveals pathognomonic polyglucosan inclusions (Lafora bodies) that appear positive on periodic acid-Schiff staining.",
"   </p>",
"   <p>",
"    The mode of inheritance is autosomal recessive. Lafora body disease is caused by mutations in the EPM2A and EPM2B genes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/67-70\">",
"     67-70",
"    </a>",
"    ], and an early-onset form of Lafora body disease may be caused by a mutation in the PRDM8 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The EPM2A gene codes for the protein laforin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], and the EPM2B gene codes for the protein malin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/69\">",
"     69",
"    </a>",
"    ]. Laforin has a starch binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/68\">",
"     68",
"    </a>",
"    ], while malin binds laforin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/71\">",
"     71",
"    </a>",
"    ], suggesting that both proteins interact in a cellular pathway that protects against polyglucosan accumulation and epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/69,71\">",
"     69,71",
"    </a>",
"    ]. The PRDM8 gene codes for a protein that interacts with and translocates laforin and malin to the nucleus; the mutated form may result in a deficiency of laforin and malin in the cytoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Hyperekplexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperekplexia, or 'human startle disease', is a rare disorder characterized by generalized stiffness beginning in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/73\">",
"     73",
"    </a>",
"    ]. Affected patients develop exaggerated myoclonic startle reactions that may result in falling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both hereditary and sporadic hyperekplexia are genetically heterogeneous. The hereditary form (MIM 149400) is typically caused by mutations in the gene coding for the inhibitory glycine receptor alpha-1 subunit (GLRA1) on chromosome 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/74\">",
"     74",
"    </a>",
"    ]. The disorder is also caused by mutations in the beta subunit of the inhibitory glycine receptor (GLRB) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/75\">",
"     75",
"    </a>",
"    ], by mutations in the gephyrin gene (GPHN) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/76\">",
"     76",
"    </a>",
"    ], and by mutations in SLC6A5, which encodes the presynaptic glycine transporter-2 (GlyT2) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SLC6A5 mutations are predominately associated with recessive hyperekplexia; symptoms include life-threatening neonatal apnea and breath-holding spells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other types of symptomatic (secondary) myoclonus include the following (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ramsay Hunt syndrome is a group of heterogeneous disorders characterized by a combination of progressive myoclonus and cerebellar ataxia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link&amp;anchor=H3#H3\">",
"       \"Symptomatic (secondary) myoclonus\", section on 'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subacute sclerosing panencephalitis after viral encephalitis (eg, measles) may present with progressive dementia and slow myoclonus that occurs at a rate of approximately one per second and is associated with periodic complexes on EEG.",
"     </li>",
"     <li>",
"      Opsoclonus-myoclonus syndrome or \"dancing eyes-dancing feet\" syndrome may occur in young children after a febrile viral illness or as a paraneoplastic syndrome associated with neuroblastoma. This disorder often improves with steroid therapy. The pathogenesis is thought to be immune mediated, but the precise mechanism remains unclear. One study found that B and T cell markers correlated with neurologic severity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/78\">",
"       78",
"      </a>",
"      ], and another found evidence of autoantibody reactivity to a neuronal surface antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/79\">",
"       79",
"      </a>",
"      ], but no single antibody has been consistently identified in children with this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?17/40/18058/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small myoclonic jerks (minipolymyoclonus) may occur in children with chronic spinal muscular atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of myoclonus is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link\">",
"     \"Treatment of myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/2/34849?source=see_link\">",
"       \"Patient information: Dystonia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22512652\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tics are repeated, individually recognizable, intermittent movements or movement fragments that are almost always briefly suppressible and are usually associated with awareness of an urge to perform the movement (",
"      <a class=\"graphic graphic_table graphicRef61505 \" href=\"UTD.htm?20/1/20508\">",
"       table 1",
"      </a>",
"      ). Multiple motor and vocal (phonic) tics are the hallmark of Tourette syndrome, a common movement and neurobehavioral disorder in children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tic disorders'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link\">",
"       \"Tourette syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dystonia is characterized by involuntary sustained or intermittent muscle contractions that cause twisting and repetitive movements, abnormal postures, or both. Dystonic states are classified as primary, secondary, or psychogenic depending upon the cause (",
"      <a class=\"graphic graphic_table graphicRef70477 \" href=\"UTD.htm?7/54/8045\">",
"       table 2A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51622 \" href=\"UTD.htm?10/38/10861\">",
"       table 2B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63377 \" href=\"UTD.htm?35/50/36652\">",
"       table 2C",
"      </a>",
"      ). By definition, primary dystonia is associated with no other neurologic impairment. However, tremor that appears identical to essential tremor occurs in approximately 20 percent of patients with this condition. Cerebral palsy probably is the most common cause of secondary dystonia seen in children. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dystonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stereotypies are repetitive, simple movements that can be voluntarily suppressed. Examples include repetitive chewing, rocking, twirling, or touching movements. These typically occur in children with infantile autism or mental retardation (",
"      <a class=\"graphic graphic_table graphicRef78875 \" href=\"UTD.htm?27/26/28075\">",
"       table 4",
"      </a>",
"      ). In addition, stereotypies also can occur in otherwise normal children. Rett syndrome is an example of a disorder characterized by marked stereotypes. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Stereotypies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link\">",
"       \"Rett syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children can be affected by many acquired and hereditary types of chorea and related movement disorders (",
"      <a class=\"graphic graphic_table graphicRef79166 \" href=\"UTD.htm?8/12/8397\">",
"       table 5",
"      </a>",
"      ). Chorea is defined as an ongoing random-appearing sequence of one or more discrete involuntary movements or movement fragments. Athetosis is defined as a slow, continuous, involuntary writhing movement that prevents maintenance of a stable posture and thus represents a form of slow chorea. Ballism (ballismus) is defined as chorea that affects proximal joints such as shoulder or hip, leading to large amplitude movements of the limbs, sometimes with a flinging or flailing quality; it is usually unilateral (hemiballismus) and often results from a lesion in the contralateral subthalamic nucleus and adjacent structures. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Chorea, athetosis, and ballismus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tremor is a rhythmic back-and-forth or oscillating involuntary movement about a joint axis and occurs at a relatively symmetric velocity in both directions about a midpoint of the movement. Although of relatively constant frequency, the amplitude may be variable. Tremor is caused by either alternating or synchronous contractions of antagonistic muscles (",
"      <a class=\"graphic graphic_table graphicRef69074 \" href=\"UTD.htm?3/3/3133\">",
"       table 6",
"      </a>",
"      ). By definition, tremor should be the only neurologic manifestation of essential tremor (ET), which is usually a benign condition. However, ET may progress to a disabling movement disorder. Two forms of hereditary ET that can begin in infancy are hereditary chin tremor and shuddering attacks. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Essential tremor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myoclonus is a sequence of repeated, often nonrhythmic, brief shock-like jerks due to sudden involuntary contraction or relaxation of one or more muscles. Myoclonus is not coordinated or suppressible and is often activated by volitional movement. Myoclonus can be physiologic or pathologic and can occur as an isolated disorder or associated with seizures or other conditions (",
"      <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Albanese A, Jankovic J. Distingushing clinical features of hyperkinetic disorders. In: Hyperkinetic Movement Disorders, Albanese A, Jankovic J.  (Eds), Wiley-Blackwell, Oxford 2012. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/2\">",
"      Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/3\">",
"      Neychev VK, Gross RE, Leh&eacute;ricy S, et al. The functional neuroanatomy of dystonia. Neurobiol Dis 2011; 42:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/4\">",
"      Tarsy D, Simon DK. Dystonia. N Engl J Med 2006; 355:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/5\">",
"      Rosenkranz K, Williamon A, Butler K, et al. Pathophysiological differences between musician's dystonia and writer's cramp. Brain 2005; 128:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/6\">",
"      Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain 1998; 121 ( Pt 2):243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/7\">",
"      Opal P, Tintner R, Jankovic J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord 2002; 17:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/8\">",
"      Brain neurotransmitters in dystonia. N Engl J Med 1987; 316:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/9\">",
"      Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998; 44:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/10\">",
"      Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord 2005; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/11\">",
"      van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999; 319:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/12\">",
"      Derinoz O, Caglar AA. Drug-induced movement disorders in children at paediatric emergency department: 'dystonia'. Emerg Med J 2013; 30:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/13\">",
"      Kanburoglu MK, Derinoz O, Cizmeci MN, Havali C. Is acute dystonia an emergency? Sometimes, it really is! Pediatr Emerg Care 2013; 29:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/14\">",
"      Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978; 135:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/15\">",
"      Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011; 11:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/16\">",
"      Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother 2010; 10:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/17\">",
"      Yang H, Wang D, Engelstad K, et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol 2011; 70:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/18\">",
"      Jankovic J. Treatment of dystonia. Lancet Neurol 2006; 5:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/19\">",
"      Mahone EM, Bridges D, Prahme C, Singer HS. Repetitive arm and hand movements (complex motor stereotypies) in children. J Pediatr 2004; 145:391.",
"     </a>",
"    </li>",
"    <li>",
"     Jankovic, J. Stereotypies in autistic and other childhood disorders. In: Paediatric Movement Disorders, Fernandez-Alvarez, E, Arzimanoglou, A, Tolosa, E (Eds), John Libbey Eurotex Limited, Montrouge, France 2005. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/21\">",
"      Kuban KC, Leviton A. Cerebral palsy. N Engl J Med 1994; 330:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/22\">",
"      Eshel G, Lahat E, Azizi E, et al. Chorea as a manifestation of rheumatic fever--a 30-year survey (1960-1990). Eur J Pediatr 1993; 152:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/23\">",
"      Cardoso F, Vargas AP, Oliveira LD, et al. Persistent Sydenham's chorea. Mov Disord 1999; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/24\">",
"      Medlock MD, Cruse RS, Winek SJ, et al. A 10-year experience with postpump chorea. Ann Neurol 1993; 34:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/25\">",
"      Brunberg JA, Doty DB, Reilly EL. Choreoathetosis in infants following cardiac surgery with deep hypothermia and circulatory arrest. J Pediatr 1974; 84:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/26\">",
"      Wong PC, Barlow CF, Hickey PR, et al. Factors associated with choreoathetosis after cardiopulmonary bypass in children with congenital heart disease. Circulation 1992; 86:II118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/27\">",
"      du Plessis AJ, Bellinger DC, Gauvreau K, et al. Neurologic outcome of choreoathetoid encephalopathy after cardiac surgery. Pediatr Neurol 2002; 27:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/28\">",
"      Huntley DT, al-Mateen M, Menkes JH. Unusual dyskinesia complicating cardiopulmonary bypass surgery. Dev Med Child Neurol 1993; 35:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/29\">",
"      Kupsky WJ, Drozd MA, Barlow CF. Selective injury of the globus pallidus in children with post-cardiac surgery choreic syndrome. Dev Med Child Neurol 1995; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/30\">",
"      Thobois S, Bozio A, Ninet J, et al. Chorea after cardiopulmonary bypass. Eur Neurol 2004; 51:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/31\">",
"      Bergman I, Steeves M, Burckart G, Thompson A. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. J Pediatr 1991; 119:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/32\">",
"      Lane JC, Tennison MB, Lawless ST, et al. Movement disorder after withdrawal of fentanyl infusion. J Pediatr 1991; 119:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/33\">",
"      Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/34\">",
"      Martich-Kriss V, Kollias SS, Ball WS Jr. MR findings in kernicterus. AJNR Am J Neuroradiol 1995; 16:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/35\">",
"      Perlman JM, Volpe JJ. Movement disorder of premature infants with severe bronchopulmonary dysplasia: a new syndrome. Pediatrics 1989; 84:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/36\">",
"      de Vries BB, Arts WF, Breedveld GJ, et al. Benign hereditary chorea of early onset maps to chromosome 14q. Am J Hum Genet 2000; 66:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/37\">",
"      Breedveld GJ, van Dongen JW, Danesino C, et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet 2002; 11:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/38\">",
"      Gras D, Jonard L, Roze E, et al. Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry 2012; 83:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/39\">",
"      Armstrong MJ, Shah BB, Chen R, et al. Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. Mov Disord 2011; 26:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/40\">",
"      Willemsen MA, Breedveld GJ, Wouda S, et al. Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr 2005; 164:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/41\">",
"      Carr&eacute; A, Szinnai G, Castanet M, et al. Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case. Hum Mol Genet 2009; 18:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/42\">",
"      Suchowersky O, Hayden MR, Martin WR, et al. Cerebral metabolism of glucose in benign hereditary chorea. Mov Disord 1986; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/43\">",
"      Kuwert T, Lange HW, Langen KJ, et al. Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography. J Neurol 1990; 237:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/44\">",
"      Schrag A, Quinn NP, Bhatia KP, Marsden CD. Benign hereditary chorea--entity or syndrome? Mov Disord 2000; 15:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/45\">",
"      Asmus F, Devlin A, Munz M, et al. Clinical differentiation of genetically proven benign hereditary chorea and myoclonus-dystonia. Mov Disord 2007; 22:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/46\">",
"      Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology 2005; 64:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/47\">",
"      Mak BS, Chi CS, Tsai CR, et al. New mutations of the HPRT gene in Lesch-Nyhan syndrome. Pediatr Neurol 2000; 23:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/48\">",
"      Puig JG, Torres RJ, Mateos FA, et al. The spectrum of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Clinical experience based on 22 patients from 18 Spanish families. Medicine (Baltimore) 2001; 80:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/49\">",
"      Jinnah HA, Ceballos-Picot I, Torres RJ, et al. Attenuated variants of Lesch-Nyhan disease. Brain 2010; 133:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/50\">",
"      Jinnah HA, Visser JE, Harris JC, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006; 129:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/51\">",
"      Elble R, Deuschl G. Milestones in tremor research. Mov Disord 2011; 26:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/52\">",
"      Gulcher JR, J&oacute;nsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet 1997; 17:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/53\">",
"      Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord 1998; 13:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/54\">",
"      Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics 2004; 114:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/55\">",
"      Jarman PR, Wood NW, Davis MT, et al. Hereditary geniospasm: linkage to chromosome 9q13-q21 and evidence for genetic heterogeneity. Am J Hum Genet 1997; 61:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/56\">",
"      Vanasse M, Bedard P, Andermann F. Shuddering attacks in children: an early clinical manifestation of essential tremor. Neurology 1976; 26:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/57\">",
"      Kanazawa O. Shuddering attacks-report of four children. Pediatr Neurol 2000; 23:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/58\">",
"      Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/59\">",
"      K&auml;lvi&auml;inen R, Khyuppenen J, Koskenkorva P, et al. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008; 49:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/60\">",
"      Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006; 47:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/61\">",
"      Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997; 386:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/62\">",
"      Virtaneva K, D'Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 1997; 15:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/63\">",
"      Pennacchio LA, Lehesjoki AE, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/64\">",
"      Serratosa JM, Gardiner RM, Lehesjoki AE, et al. The molecular genetic bases of the progressive myoclonus epilepsies. Adv Neurol 1999; 79:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/65\">",
"      Berkovic SF, Mazarib A, Walid S, et al. A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain 2005; 128:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/66\">",
"      Karimipour D, Lowe L, Blaivas M, et al. Lafora disease: diagnosis by skin biopsy. J Am Acad Dermatol 1999; 41:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/67\">",
"      Ganesh S, Agarwala KL, Ueda K, et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet 2000; 9:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/68\">",
"      Minassian BA, Ianzano L, Meloche M, et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 2000; 55:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/69\">",
"      Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 2003; 35:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/70\">",
"      Lohi H, Turnbull J, Zhao XC, et al. Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology 2007; 68:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/71\">",
"      Chan EM, Omer S, Ahmed M, et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 2004; 63:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/72\">",
"      Turnbull J, Girard JM, Lohi H, et al. Early-onset Lafora body disease. Brain 2012; 135:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/73\">",
"      Tijssen MA, Voorkamp LM, Padberg GW, van Dijk JG. Startle responses in hereditary hyperekplexia. Arch Neurol 1997; 54:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/74\">",
"      Shiang R, Ryan SG, Zhu YZ, et al. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993; 5:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/75\">",
"      Rees MI, Lewis TM, Kwok JB, et al. Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). Hum Mol Genet 2002; 11:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/76\">",
"      Rees MI, Harvey K, Ward H, et al. Isoform heterogeneity of the human gephyrin gene (GPHN), binding domains to the glycine receptor, and mutation analysis in hyperekplexia. J Biol Chem 2003; 278:24688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/77\">",
"      Rees MI, Harvey K, Pearce BR, et al. Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat Genet 2006; 38:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/78\">",
"      Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004; 62:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/79\">",
"      Blaes F, F&uuml;hlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/40/18058/abstract/80\">",
"      Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012; 27:935.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6232 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18058=[""].join("\n");
var outline_f17_40_18058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22512652\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY OF THE BASAL GANGLIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DYSTONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DYT1 dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dopa-responsive dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Paroxysmal dyskinesia with dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hemidystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute dystonic reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192849077\">",
"      Neurodegeneration with brain iron accumulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STEREOTYPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHOREA, ATHETOSIS, AND BALLISMUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physiologic chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Sydenham chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Post pump chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other acquired causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hereditary chorea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Benign hereditary chorea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Lesch-Nyhan syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ESSENTIAL TREMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hereditary chin tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Shuddering attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MYOCLONUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Benign neonatal sleep myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Essential myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cortical myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Epilepsia partialis continua",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Unverricht-Lundborg disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Lafora body disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Hyperekplexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22512652\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/1/20508\" title=\"table 1\">",
"      Classification of tics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/54/8045\" title=\"table 2A\">",
"      Etiology of dystonia a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/38/10861\" title=\"table 2B\">",
"      Etiology of dystonia b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/50/36652\" title=\"table 2C\">",
"      Etiology of dystonia c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/8/7310\" title=\"table 3\">",
"      Genetic forms dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/26/28075\" title=\"table 4\">",
"      Disorders with stereotypies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/12/8397\" title=\"table 5\">",
"      Etiology of chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/3/3133\" title=\"table 6\">",
"      Classification of tremors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/60/21455\" title=\"table 7\">",
"      Clinical etiologic classification myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=related_link\">",
"      Classification and evaluation of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=related_link\">",
"      Clinical features and electrodiagnosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/2/34849?source=related_link\">",
"      Patient information: Dystonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19737?source=related_link\">",
"      Pharmacologic treatment of essential tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=related_link\">",
"      Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28741?source=related_link\">",
"      Surgical treatment of essential tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22007?source=related_link\">",
"      Sydenham chorea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=related_link\">",
"      Treatment of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=related_link\">",
"      Treatment of myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_40_18059="Etiology and frequency of esophageal perforation";
var content_f17_40_18059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology and frequency of esophageal perforation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology of esophageal perforation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic",
"       </td>",
"       <td class=\"centered\">",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous",
"       </td>",
"       <td class=\"centered\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body ingestion",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Operative injury",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table depicts the causes of esophageal perforation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18059=[""].join("\n");
var outline_f17_40_18059=null;
var title_f17_40_18060="Empiric treatment for pyelonephritis in pregnancy";
var content_f17_40_18060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral regimens for empiric treatment of pyelonephritis in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose, interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Mild to moderate pyelonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        1 g every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefepime",
"       </td>",
"       <td>",
"        1 g every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aztreonam*",
"       </td>",
"       <td>",
"        1 g every 8 to 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;",
"        <p>",
"         Ampicillin",
"        </p>",
"        <p>",
"         PLUS",
"        </p>",
"        <p>",
"         Gentamicin&bull;",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"        <p>",
"         1-2 g every 6 hours",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         1.5 mg/kg every 8 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Severe pyelonephritis with immunocompromise and/or incomplete urinary drainage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ticarcillin-clavulanate",
"       </td>",
"       <td>",
"        3.1 g every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Piperacillin-tazobactam",
"       </td>",
"       <td>",
"        3.375 g every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meropenem",
"       </td>",
"       <td>",
"        500 mg every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ertapenem&nbsp;",
"       </td>",
"       <td>",
"        1 g every 24 hours&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doripenem",
"       </td>",
"       <td>",
"        500 mg every&nbsp;8 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Doses are for patients with normal renal function.",
"    <br>",
"     The treatment of urinary tract infection due to enterococcus is discussed separately.",
"     <br>",
"      If methicillin-resistant S. aureus (MRSA) is known or suspected, see treatment regimens outlined separately in topics addressing MRSA management.",
"      <div class=\"footnotes\">",
"       * Alternative in the setting of beta lactam allergy.",
"       <br>",
"        &bull; Aminoglycosides have been associated with fetal ototoxicity (United States Food and Drug Administration&nbsp;category D); &nbsp;this regimen should be used only if intolerance precludes the use of less toxic agents.",
"       </br>",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18060=[""].join("\n");
var outline_f17_40_18060=null;
var title_f17_40_18061="Sx neuropsychiatric lupus";
var content_f17_40_18061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neuropsychiatric manifestations of systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Primary neurological manifestations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            CVA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Vasculopathy (atherosclerosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Emboli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Libman-Sacks",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiphospholipid antibodies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Generalized",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Partial complex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Migraine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Transeverse myelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Optic neuritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Organic brain syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psychosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cognitivie defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Dementia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuropathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Primary psychiatric manifestations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cognitive disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudo dementia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Functional",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anxiety",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Headache",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Conversion reaction",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary complications, systemic disease, chronic disease, and/or its treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neurologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            CVA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Uremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Psychiatric",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psychosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hypomania",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Coma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anxiety",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Affective disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mood swing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Adjustment disorder",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18061=[""].join("\n");
var outline_f17_40_18061=null;
var title_f17_40_18062="Event rates in SPAF III";
var content_f17_40_18062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increased stroke risk with low dose warfarin plus aspirin in AF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results from the SPAF III trial of high-risk patients showing significantly higher event rates for intracranial hemorrhage and ischemic stroke in patients treated with fixed low dose warfarin plus aspirin compared with standard adjusted-dose warfarin. The risk was greater in those with a previous thromboembolic event.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996; 348:633.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18062=[""].join("\n");
var outline_f17_40_18062=null;
var title_f17_40_18063="Loop permeability";
var content_f17_40_18063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Transport properties of different nephron segments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Passive permeability of the loop of Henle and distal nephron segments to sodium chloride, urea, and water. The generally low passive permeability to solutes (except for the descending limb) means that transport can occur only via carriers or channels. The urea permeability of the innermost part of the medullary collecting tubule is increased in the presence of ADH.",
"    <div class=\"footnotes\">",
"     ++: highly permeable; +: moderately permeable; &plusmn;: less permeable; 0: relatively impermeable.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jamison, RL, Kidney Int 1987; 21:S43, and Sands, JM, Am J Physiol 1987; 253:F823.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_40_18063=[""].join("\n");
var outline_f17_40_18063=null;
